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Neurogenic activityrecently described X-ray free-electron laser (XFEL) structures of chimeric MT1R and MT2R, provided a
rationale for the experimental data and afforded valuable insights for future drug design endeavours.
© 2020 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Alzheimer’s disease (AD) is the most common age-associated
neurodegenerative disorder (ND), whose main hallmarks are the
extracellular deposits of the misfolded amyloid-b peptide (Ab), the
intracellular accumulation of the hyperphosphorylated
microtubule-associated tau protein and amassive neuronal loss [1].
AD aetiology is not completely understood, although different
causative factors have been postulated, such as oxidative stress and
neuroinflammation [2].
Oxidative stress is the consequence of the progressive failure of
the antioxidant defence systems, particularly noticeable in the
brains of AD-patients, where the increased levels of oxidized bio-
molecules correlate to disease progression [3]. Thereby, the control
of transcription factors involved in the regulation of antioxidant
genes and the inhibition of the main enzymes that produce reactive
oxygen and nitrogen species (ROS and RNS) would be a valuable
strategy to combat AD [4].
The nuclear erythroid 2-related factor (NRF2) is a transcriptional
protein that regulates the expression of antioxidant and anti-
inflammatory enzymes [5]. In non-stressed conditions, NRF2 is
mainly located in the cytosol bound to the Kelch-like ECH associ-
ated protein 1 (KEAP1), which favours its proteasome degradation.
Under pathological conditions (oxidative stress, toxic insults, etc.),
KEAP1 changes its conformation and NRF2 is released and trans-
located to the nucleus, where it binds to the DNA antioxidant
response elements (AREs), inducing the expression of antioxidant
enzymes such as NAD(P)H quinone oxidoreductase and heme
oxygenase-1 [6,7].
Monoamine oxidases (MAO-A and MAO-B) are outer mito-
chondrial membrane-bound flavoproteins, whose levels are
increased in the brain of patients suffering NDs, such as AD and
Parkinson’s disease. Both enzymes catalyse the oxidative deami-
nation of biogenic amines, including several neurotransmitters,
what it produces hydrogen peroxide, ROS, and accordingly oxida-
tive stress [8]. Besides, overexpression of MAO-B increases the
formation of aberrant Ab [9]. In this regard, MAO inhibition could
provide neuroprotection against AD, by regulating neurotransmit-
ters’ levels, ameliorating oxidative pathologies and stopping the
deposition of amyloid plaques.
Neuroinflammation is another important player in AD that
generates cytokines and neurotoxins, leading to neuronal damage
and death [10]. The iron-containing enzyme lipoxygenase-5 (LOX-
5, EC 1.13.11.34) catalyses two early steps of the oxidation of the
arachidonic acid, producing finally pro-inflammatory leukotrienes
[11]. LOX-5 is present in the CNS particularly in the hippocampus,
where its levels appear to increase in AD [12]. Several works have
demonstrated that blockade of LOX-5 in transgenic mice di-
minishes cytokines levels and both Ab and tau pathologies [13,14].
Therefore, LOX-5 inhibitors could be valuable therapeutic agents, as
they could reduce neuroinflammation and aberrant protein
aggregation.
Inmammals, melatonin is secreted in nanomolar concentrations
from the pineal gland to the blood, when it transmits the circadian
rhythm to the peripheral organs by interacting with two G-protein-
coupled receptors (GPCRs), called MT1 and MT2 (MT1R and MT2R)
[15]. Melatonin also interacts with a third binding site, MT3, which
has been identified as the flavin adenine dinucleotide (FAD)-dependent enzyme quinone reductase-2 (QR2, EC 1.10.99.2) [16,17].
Melatonin activates MT1R and MT2R at sub-nanomolar concentra-
tions (Kd ~ 0.1 nM), whereas its affinity as a QR2 inhibitor is about
100-fold lower [16].
QR2 catalyses the two-electron reduction of quinones into un-
stable hydroquinones, which are excreted through conjugation or
reconverted to quinones in the presence of oxygenwhile producing
ROS [18]. Given that QR2 levels are increased in the hippocampus of
AD patients, inhibitors of this enzyme are promising therapeutic
agents to fight neurodegeneration by reducing the oxidative stress
[19e21].
Adult neurogenesis is a matter of intense research, although its
scope and function remain debatable [22,23]. Restricted to small
regions, namely the subventricular zone (SVZ) of the lateral
ventricle and the subgranular zone (SGZ) of the hippocampus, the
adult mammalian brain retains neural stem cells (NSC) niches that
could develop and integrate new cells in the neuronal circuitry.
Therefore, a neurogenic drug would induce the differentiation of
NSCs into mature neurons capable of replacing those lost by neu-
rodegeneration, allowing the brain to recover its own self-renewal
capacity [24].
In recent years, numerous molecular targets and signalling
cascades involved in neurogenesis have been identified and, as a
consequence, different types of drugs have been evaluated in
neuronal regeneration. For example, neurogenic properties have
been found in MTRs’ ligands, NRF2 activators, antioxidants and
anti-inflammatory agents [25].
Melatonin modulates hippocampal neurogenesis by increasing
both cellular precursor proliferation and survival in the hippocampi
of aged mice [26]. Given these outstanding properties, many
research groups (including ours) have devoted great efforts aimed
to the identification of new MTR ligands and their molecular
interaction pathways [27e30]. In this context, our melatonin
analogue IQM316 was recently found to be capable of inducing
hippocampal neurogenesis in mice at a healthy and sustainable
rate, thus helping to preserve previous memories [31,32]. We have
also described the bioisosteric replacement of the acetamido group
of melatonin by a series of reversed amides and azoles [29]. Among
these azole derivatives, 5-[2-(5-methoxy-1H-indol-3-yl)ethyl]-
1,3,4-oxadiazol-2(3H)-one (1) was the most potent partial agonist
at the human MTRs, displaying the highest affinity for both human
MTRs (Ki ¼ 35 and 4 nM for hMT1R and hMT2R, respectively).
Moreover, this compound also showed potent neurogenic proper-
ties in vitro, better than melatonin itself, but it was predicted that it
would not enter the CNS in view of the unfavourable results in
in vitro blood-brain barrier (BBB) permeability assays.
Given the complex nature of AD, the multi-target directed
ligand (MTDL) strategy has emerged as a valid alternative to fight
different pathological cascades involved in this disease. To achieve
maximum efficiency, MTDLs should promote endogenous defen-
sive and/or regenerative pathways and be directed towards bio-
molecular targets located upstream in the neurotoxic cascades
[2,33].
With these ideas in mind, in this work we planned to develop
new melatonin-based MTDLs that could improve the CNS perme-
ability of 1 and also incorporate additional activities on targets
related to oxidative stress and neuroinflammation. For this pur-
pose, wemodified each part of the startingmolecule by: (i) addition
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replacement of the oxadiazolone ring by an oxadiazolamine; (iii)
insertion of a double bond in the linker; and (iv) replacement of the
indole by a dihydronaphthalene or naphthalene ring (Figure 1).
2. Results and discussion
2.1. Chemistry. Synthesis of new indole- and naphthalene-based
compounds
The microwave (MW)-assisted reaction (120 C, 10 min) of 1Scheme 1. Reagents and conditions: (a) RX, K2CO3, acetone, MW, 120 C, 10 min; (b) RNH2, B
(5%), EtOH, rt, overnight; (e) N2H4$H2O, MW, 150 C, 45 min; (f) CDI, DMF, MW, 120 C, 25 m
ACN, rt, 3 h; (i) N2H4$H2O, rt; (j) Propargyl bromide, K2CO3, acetone, MW, 120 C, 10 min;
Fig. 1. Design strategy for the nowith the corresponding alkyl halide in basic media (K2CO3) using
acetone as solvent gave derivatives 2e15, in moderate to excellent
yields (49e92%) (Scheme 1).
Moreover, the treatment of 1 with methyl- or ethylamine in the
presence of (benzotriazol-1-yloxy)tris(dimethylamino)phospho-
nium hexafluorophosphate (BOP) and triethylamine (TEA) in DMF,
yielded 1,3,4-oxadiazol-2-amines (16 and 17) in low yields (18 and
6%, respectively).
Modifications in the linker were performed using the
commercially available 5-methoxy-1H-indole-3-carbaldehyde (18)
as starting material. The introduction of a methyl group in the beta-OP, TEA, DMF, rt, overnight; (c) Ph3P]CHeCO2Et, DCM, reflux, overnight; (d) H2/PdeC
in; (g) Malonic acid, piperidine, pyridine, 70 C, overnight; (h) HOBt, EDC$HCl, DMAP,
(k) Propargylamine or allylamine, rt.
vel melatonin-based MTDLs.
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(carbethoxyethylidene)triphenylphosphorane by a Wittig reaction,
giving the corresponding a,b-unsaturated ester 19 in high yields
(95%). Then, 19 was reduced by catalytic hydrogenation to the
saturated ester 20, followed by its transformation to the corre-
sponding hydrazide and further MW-assisted cyclization in the
presence of 1,1-carbonildiimidazole (CDI) to give the 1,3,4-
oxadiazol-2(3H)-one derivative 21 in 48% yield.
The conjugated double bond in the linker was introduced by the
treatment of 18 with malonic acid in basic media that generate the
a,b-unsaturated acid 22, in almost quantitative yield by a Knoeve-
nagel-Doebner reaction. Activation of 22with hydroxybenzotriazole
(HOBt) and N-(3-dimethylaminopropyl)-N0-ethylcarbodiimide hy-
drochloride (EDC$HCl) as coupling agents, and a catalytic amount of
4-dimethylaminopyridine (DMAP) at rt during 3 h, followed by the
addition of hydrazine hydrate, yielded the corresponding hydrazide
in quantitative yield. It is worth-mentioning that the order of
addition of the reagents is crucial for obtaining high yields. Once
the hydrazide is formed, its MW-assisted cyclization with CDI
afforded the indoleeNH-oxadiazolone derivative 23 in good yield
(85%). The treatment of 23 with propargyl bromide in basic media
(K2CO3) and acetone in an MW-oven at 120 C during 10 min
afforded the corresponding N-propargyl-oxadiazolone 24 (Scheme
1). Bioisosteric replacement of the oxadiazolone ring by an amide
group was carried out from the a,b-unsaturated acid 22 by
condensation with propargyl or allyl amine in acetonitrile at rt
during 3 h, in the presence of EDC$HCl, HOBt, and DMAP, giving the
corresponding propargyl (25) or allyl derivative (26) in moderate to
good yields (Scheme 1).
Indole scaffold replacement by either a dihydronaphthalene or a
naphthalene ring was carried out from commercial 7-methoxy-1-
tetralone (27) by two different synthetic routes. Reaction of 27
with a solution of methyl magnesium iodide in ether at rt for 3 h
afforded the corresponding alcohol (non-isolated intermediate),
which was treated with HCl to yield the 1-methyl dihydronaph-
thalene 28 in quantitative yield [34]. Oxidation of the above methyl
group with selenium dioxide gave aldehyde 29, in low yield due to
the easy aromatization of the dihydronaphthalene ring. In spite of
the mild oxidative conditions used, a mixture of dihydronaph-
thalene 29 and naphthalene 30 [35] was obtained, in 25% and 20%Scheme 2. Reagents and conditions: (a) CH3MgI, Et2O, rt, 3 h; (b) 2 M HCl, 40 C, 3 h; (c)
overnight; (e) EDC$HCl, HOBt, DMAP, ACN, rt, 3 h; (f) N2H4$H2O, rt; (g) CDI, DMF, MW, 120 
MW, 105 C, 15 min; (j) LiOH, THF:H2O (1:1), rt, overnight.yield respectively (Scheme 2).
Then, we planned to transform the dihydronaphthalene deriv-
ative 29 into the unsaturated acid 31 by the treatment withmalonic
acid in Knoevenagel-Doebner conditions, obtaining unexpected 1H
and 13C NMR data for the isolated product. A deeper NMR analysis
(COSY, HSQC, and HMBC) demonstrated that this structure corre-
sponded to lactone 32, formed under basic conditions by an
intramolecular cyclization (Scheme 2). Probably, the carboxylate
group attacked the intracyclic double bond forming the interme-
diate enol, which could develop to lactone 32. Nevertheless, given
that in solution this cyclization is an equilibrium, acid activation
was possible after treatment with coupling reagents (EDC$HCl,
HOBt). Further treatment with N2H4$H2O and CDI, led to the
desired dihydronaphthalene-based NH-oxadiazolone 33, although
in low yield (15%), probably due to the easy aromatization that
could also give the corresponding naphthalene (non-isolated).
Aiming to improve the yield of the oxadiazolone derivative with
a dihydronaphthalene core 33, another alternative synthetic route
was explored. 7-Methoxy-1-tetralone (27) was reacted with tri-
fluoromethanesulfonic anhydride (Tf2O) and 2-chloropyridine as
base to yield the vinyl triflate 34 in good yield (78%) [36] (Scheme
2).
Then, the introduction of an a,b-unsaturated ester was carried
out by olefination of vinyl triflates under palladium-catalysed
conditions (Heck reaction), using ethyl acrylate as reactant and
TEA as base. Since first attempts to obtain 35 in good yields failed,
different experimental conditions in a MW oven were probed,
modifying the palladium-based catalyst [Pd(OAc)2þPPh3 or
Pd(PPh3)2Cl2], temperature (100e140 C) and reaction time
(10e40 min). Optimized conditions for the synthesis of 35 resulted
from the use of Pd(PPh3)2Cl2 as catalyst and MW irradiation at
105 C for 15 min, obtaining the desired ester derivative in 87%
yield.
Then, the ester 35 was hydrolysed under basic condition with
lithium hydroxide (LiOH) followed by acid treatment with HCl to
obtain the corresponding acid. This acid was not isolated but
transformed into the corresponding hydrazide, followed by cycli-
zation with CDI to afford the desired dihydronaphthalene-based
oxadiazolone 33 in low yields (21%) due to its easy aromatization.
In fact, the aromatic analogue was detected by HPLC-MS, althoughSeO2, EtOH:H2O (10:1), reflux, overnight; (d) Malonic acid, piperidine, pyridine, 70 C,
C, 25 min; (h) Tf2O, 2-chloropyridine, DCM, 2 h, rt; (i) Ethyl acrylate, Pd(PPh3)2Cl2, TEA,
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Given that the best yields were achieved using the Heck reaction
in triflate derivatives, this strategy was applied for obtaining
naphthalene derivatives. The conditions previously used in the
synthesis of the vinyl triflate 34 (Scheme 2) were extended to the
dimethoxylated derivative (Scheme 3). However, derivative 37 was
obtained in low yields due to the formation of several by-products,
probably due to the lesser electrophilic character of the carbonyl
group. Aromatization of triflates 34 and 37 with 2,3-dichloro-5,6-
dicyano-1,4-benzoquinone (DDQ) at rt, led naphthalenes 38 and
39, respectively (Scheme 3). Then, the ethyl acrylic moiety was
introduced by a Heck reaction, treating the corresponding triflate
derivative with ethyl acrylate in the presence of Pd(OAc)2, 1,10-
phenanthroline and TEA, to yield naphthalene esters 40 and 41 in
high yields (90 and 81%, respectively). These esters were hydro-
lysed under basic conditions, obtaining acids 42 and 43 in quanti-
tative yields. Finally, these acids were transformed into the
corresponding hydrazides, followed by cyclization with CDI to
afford naphthaleneeNH-oxadiazolones 44 and 45 in good yields
(91 and 85%, respectively).
All new compounds were isolated and purified using flash col-
umn chromatography (automatic IsoleraOne-Biotage equip), pre-
parative thin-layer plates (TLC) or semipreparative HPLC (Waters
Autopurification system). Purity (>95%) was evaluated by HPLC-MS
and chemical structure was characterized by their spectroscopic
data (1H NMR, 13C NMR). Complete NMR assignments were made
by two-dimensional NMR experiments, mainly COSY (homonuclear
correlation spectroscopy), HSQC (heteronuclear single quantum
correlation) and HMBC (heteronuclear multiple bond correlation).
2.2. Characterization in melatonin receptors
Experiments on human MT1R and MT2R were performed in
Chinese hamster ovary cells, where these receptors were stably
transfected. The QR2 binding assays were carried out using mem-
brane homogenates of hamster brains. In all cases, displacement of
the radioligand 2-[125I]iodomelatoninwasmeasured in the absenceScheme 3. Reagents and conditions: (a) Tf2O, 2-chloropyridine, DCM, rt, 2 h; (b) DDQ, DCM
LiOH, THF:H2O 1:1, rt, overnight; (e) 1 M HCl; (f) EDC$HCl, HOBt, DMAP, ACN, rt; (g) N2H4$or presence of the tested compound and nonspecific binding was
determined with melatonin, following described protocols
[37e39].
Firstly, radioligand displacements were measured at a fixed
concentration of compound (100 or 10,000 nM) in each receptor
subtype. Then, binding constants (Ki) were calculated only for
compounds with a radioligand displacement above 80%, using a
range of 5 different concentrations of tested compound in 3 inde-
pendent experiments. Melatonin was assayed for comparative
purposes and results are gathered in Table 1.
The indoleeNH-oxadiazolone 1 showed high binding affinities
for hMT1R and hMT2R (Ki ¼ 35 and 4 nM, respectively) [29]. In
contrast, it did not show a substantial affinity toward QR2, as it only
displaced 5% of the radioligand at 100 nM (Table 1). The intro-
duction of substituents in the NH group of the oxadiazolone ring to
give derivatives 2e15 caused a great decrease in the affinity for all
melatonin receptors, reaching in some cases the total loss of ac-
tivity. Only compounds with longer chains namely, 7 [R ¼
(CH2)5CH3], 8 [R ¼ (CH2)6CH3], 12 (R ¼ CH2cyclobutyl), 13
(R ¼ CH2cyclopentyl), and 15 [R ¼ (CH2)3phenyl] showed a slight
selectivity for hMT2R over hMT1R, with binding constants around
107 M in the case of hMT2R. This affinity drop could be due to a
possible hydrogen bond between the NH group of the oxadiazolone
ring of 1 and the receptors, which is lost when it is substituted. The
evaluation of derivative 4 in QR2 gave only a 68% displacement at
10 mM, so its Ki was not calculated and the rest of the indole-
oxadiazolones were not evaluated in QR2.
The replacement of the oxadiazolone ring by a 1,3,4-oxadiazol-
2-amine to give 16 provided binding constants in the hundred-
nanomolar range for the three melatonin targets (Ki ¼ 550, 110,
and 330 nM, for hMT1R, hMT2R and QR2, respectively). Thus, this
change maintained the binding constants for hMT1R and hMT2R
and improved the affinity for QR2, compared to some N-substituted
oxadiazolone derivatives (e.g., 12 and 15).
The addition of a methyl group in the aliphatic linker of 1 to give
the beta-methyl derivative 21, resulted in the complete loss of af-
finity for hMT1R, a similar binding for hMT2R (Ki ¼ 12 nM) and, rt, 10 min; (c) Ethyl acrylate, Pd(OAc)2, 1,10-phenanthroline, DMF, MW, 150 C, 1 h; (d)
H2O, rt; (h) CDI, DMF, MW, 130 C, 25 min.
Table 1
Binding constants at hMT1R, hMT2R and QR2 (Ki, nM), or percentage of radioligand displacement at the specified concentration (in brackets), antioxidant properties (ORAC,
trolox equiv.) and NRF2 induction capability (CD, mM) of new indole and naphthalene derivatives.
Compd. Ki (nM)a ORAC (Trolox equiv)b NRF2 (CD, mM)c
hMT1R hMT2R QR2
1 35 ± 1d 4.0 ± 0.5d >102 (5%) 2.7 ± 0.3 n.d.
4 >104 >104 ~104 (68%) 3.0 ± 0.2 >30
7 >104 530 ± 40 n.d. 2.1 ± 0.2 n.d.
8 >104 300 ± 30 n.d. 2.2 ± 0.1 n.d.
12 550 ± 40 230 ± 20 n.d. 2.8 ± 0.2 n.d.
13 >104 390 ± 30 n.d. 2.7 ± 0.2 n.d.
15 690 ± 60 320 ± 20 n.d. 1.8 ± 0.2 n.d.
16 550 ± 40 110 ± 20 330 ± 30 2.3 ± 0.1 n.d.
21 >102 (37%) 12 ± 0.9 220 ± 20 2.3 ± 0.1 >60
23 >102 (8%) >102 (17%) 6.6 ± 0.4 2.4 ± 0.1 15.1 ± 0.9
24 >102 (0%) >102 (0%) 3.2 ± 0.2 1.8 ± 0.1 1.76 ± 0.20
25 >102 (13%) ~102 (58%) 9.3 ± 0.5 1.3 ± 0.1 27.4 ± 1.5
26 >102 (34%) ~102 (78%) 110 ± 10 1.8 ± 0.1 >30
33 ~104 (46%) 260 ± 20 250 ± 20 0.4 ± 0.04 n.d.
44 260 ± 20 5.1 ± 0.4 270 ± 20 <0.1 >30
45 ~104 (63%) 69 ± 6 35 ± 2 <0.1 >30
Melatonin 0.27 ± 0.03 0.13 ± 0.02 77 ± 1 2.3 ± 0.1 n.d.
Sulforaphane n.d. n.d. n.d. n.d. 0.54 ± 0.07e
n.d., not determined.
a Results are the mean ± SEM of three independent experiments (n ¼ 3).
b Results are the mean ± SD of three independent experiments (n ¼ 3).
c Values are expressed as the mean ± SEM of four independent experiments in duplicate.
d Value from Ref. [29].
e Value from Ref. [40].
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Introduction of a double bond in the linker of the indole series
provided interesting effects on the behaviour of these unsaturated
oxadiazolones (23 and 24) and amides (25 and 26). These four
derivatives lost their affinities toward hMT1R and hMT2R (Kis >
100 nM), while drastically improved their binding to QR2. Unsat-
urated indole-oxadiazolone compounds 23 and 24, and the prop-
argyl amide derivative 25 showed Kis between 3.2 and 9.3 nM in
QR2, one order of magnitude better than melatonin itself
(Ki ¼ 77 nM).
According to previously published results [41], we also found
that the NH-indole fragment was not indispensable for activity on
melatonin targets. In fact, the 7-methoxy-3,4-dihydronaphthalene
33 showed affinities toward hMT2R and QR2 in the 107 M range
(Ki ¼ 410 and 260 nM, respectively), although resulted poor active
in hMT1R. Ring aromatization to give the naphthalene counterpart
greatly modified its profile, as 44 recovered amoderated affinity for
hMT1R (Ki ¼ 260 nM), maintained a similar affinity for QR2
(Ki ¼ 270 nM), and interestingly, displayed a potent binding con-
stant in hMT2R in the low-nanomolar range (Ki ¼ 5.1 nM). The
introduction of a second methoxy group in position 6 of the
naphthalene ringwas partially detrimental for affinity, since 45was
inactive in hMT1R, not as active as 44 in hMT2R (Ki ¼ 69 nM),
although 45 was one order of magnitude more active in QR2
(Ki ¼ 35 nM).
5-(2-(7-Methoxynaphthalen-1-yl)vinyl)-1,3,4-oxadiazol-2(3H)-
one (44), which displayed the highest affinity for hMT2R, was also
functionally characterized by measuring its effects on cAMP mod-
ulation, according to a described HTRF-detection protocol [38,42].
Compound 44 was found to be a potent agonist in hMT2R with a
half maximal effective concentration in the low-nanomolar range
(EC50 ¼ 1.2 ± 0.1 nM) and a maximum activity of 85% with respect
to melatonin.2.3. Evaluation of the oxygen radical absorbance capacity (ORAC)
As a measure of antioxidant properties, we tested new indole-and naphthalene-based compounds in the ORAC assay, following
described protocols [43e46]. (±)-6-Hydroxy-2,5,7,8-
tetramethylchromane-2-carboxylic acid (trolox), the aromatic
part of vitamin E responsible for its scavenging properties, was used
as the internal standard with the arbitrary value of ORAC ¼ 1.0.
Results are expressed as trolox equivalents (trolox mmol/tested
compd. mmol) in a comparative scale that indicates if a compound
is a better (ORAC > 1.0 trolox equiv) or a worse oxygen radical
scavenger (ORAC < 1.0 trolox equiv) than vitamin E. Melatonin was
also evaluated for comparative purposes, giving an ORAC value 2.3-
fold higher than trolox. This activity fully agrees with the ORAC
value previously described by Sofic et al. (2.0 trolox equiv) [47], thus
supporting the reliability of our experiments.
As shown in Table 1, all indole derivatives displayed ORAC values
ranging from 1.3 to 3.0 trolox equiv., independently of the nature of
the substituent attached to position 3 of the heterocycle. Conse-
quently, they could be considered as excellent antioxidant agents.
Surprisingly, the unsaturated derivative 23 did not show a sub-
stantial difference in the ORAC value (2.4 trolox equiv) compared to
its saturated analogue 1 (2.7 trolox equiv), despite the view that an
increase of the conjugation between the indole and oxadiazolone
rings would bring about augmented radical scavenger properties.
Replacement of indole by a dihydronaphthalene or naphthalene
core was detrimental to the antioxidant activity in the ORAC assay.
Dihydronaphthalene 33 displayed a reduced ORAC value (0.4 trolox
equiv) and naphthalenes 44 and 45 were inactive at the maximum
concentration tested (10 mM). In summary, it can be inferred that in
these compounds the radical absorbance capacity was mainly due
to the presence of the indole ring, rather than other structural
motifs.2.4. Induction of the transcription factor NRF2 pathway in the
AREc32 cell line
The ability to activate NRF2 was evaluated using an NRF2-
dependent luciferase reporter assay in the AREc32 cell line
[40,48]. Cells were cultured for 24 h and then treated with
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10 and 30 mM). A selection of new derivatives, covering different
structural features, was tested as inducers of NRF2 signalling and
the results are gathered in Table 1. Sulforaphane was used as
reference compound and data are expressed as the concentration
needed to duplicate the specific activity of the luciferase reporter
(CD).
In general, saturated indole-oxadiazolone derivatives (e.g., 4)
did not show activity at the maximum concentration tested
(30 mM). On the contrary, the unsaturated indole-oxadiazolone 23
and its N-propargylic counterpart 24 were able to increase lucif-
erase activity, with CD values of 15.1 and 1.8 mM, respectively
(Table 1). Removal of the oxadiazolone ring in 24 to give the
propargylic amide 25 caused a decrease by one order of magnitude
in NRF2 activation (CD¼ 27.4 mM). When the propargyl moiety was
replaced by an allyl fragment (26) the activity vs. NRF2 was lost.
Dihydronaphthalene and naphthalene analogues were inactive.
The above results indicated the importance of the presence of the
indole core and a double bond in the linker to achieve good in-
duction of NRF2.2.5. Binding studies by surface plasmon resonance (SPR) assay
As explained in the introduction, activation of NRF2 could be
due to conformational changes in KEAP1 that preclude the union
between both proteins and stimulate the expression of antioxidant
enzymes by NRF2. To evaluate the ability of our molecules to
interact with the Kealch domain of KEAP1, a surface plasmon
resonance (SPR) experiment was carried out. The Kelch domainwas
obtained from Escherichia coli transformed with pET15b-6xHIS-
Kelch plasmid and induced by adding isopropyl-1-thio-b-D-gal-
actopyranoside (IPTG). 6xHIS-Kelch was purified using the ProBond
Purification System (Invitrogen). The Kelch domain of KEAP1 was
immobilized on a carboxymethyl cellulose sensor chip (CM5) and a
solution of the corresponding molecule (100 mM) was then fluxed
over the sensor chip in order to detect a change in the SPR signal,
resulting from the interaction between the compounds and the
Kelch domain. The well-known KEAP1 binder ML334 was used as
internal reference [49], which produced a change in the SPR signal
of 10 resonance units (Fig. 2).
As shown in Fig. 2, SPR responses of compounds 23e25 were
equal to, or greater than ML334, while the rest of the compounds
tested (4, 21, 26, and 45) gave fewer values. Importantly, the most
active compounds in the phenotypic assay based on AREc32 cellsFig. 2. Binding of selected compounds (4, 21, 23e26 and 45) to immobilized KEAP1
Kelch domain protein in comparison with ML334, determined by SPR spectroscopy.
Mean ± SD (n ¼ 3), one-way ANOVA plus Dunnett’s test compared to ML334 (#).
**P < 0.05.showed a better binding to KEAP1 than the less active derivatives.
Therefore, we can tentatively think that the activation of NRF2 by
compounds 23e25 in the cellular assay could be due to the binding
of these molecules to KEAP1.2.6. Inhibition of human MAO and LOX-5
All compounds were evaluated as inhibitors of human MAO-A,
MAO-B and LOX-5 and the results of the most representative
compounds are collected in Table 2. For the sake of clarity, data of
inactive compounds in the three enzymes are omitted. The hMAO-
A/B inhibition was determined by the production of oxygen
peroxide from a common substrate for both isoenzymes (p-tyra-
mine) and quantified by the Amplex Red MAO assay kit [50]. (R)-
Deprenyl, iproniazid and moclobemide were also tested for
comparative purposes. The inhibition of hLOX-5 was performed
following the fluorescence-based method described by Pufahl et al.
[51], using the two well-known inhibitors zileuton and nordihy-
droguaiaretic acid (NDGA) as internal references.
In general, saturated indoleeoxadiazolone derivatives did not
show any appreciable inhibition of hMAOs or hLOX-5
(IC50 > 50 mM), with the exception of 12 and 13 which displayed a
modest inhibition of hLOX-5 (IC50¼ 74.2 and 22.5 mM, respectively).
The 5-methoxyindole-oxadiazolamine 16 inhibited both hMAO-B
and hLOX-5 (IC50 ¼ 37.0 and 60.6 mM, respectively). Introduction of
a double bond in the linker changed this profile, as the 5-
methoxyindole-oxadiazole 23 displayed moderate inhibition of
MAO-A and MAO-B (IC50 ¼ 53.0 and 68.3 mM, respectively)
although it was inactive in LOX-5 (IC50 > 100 mM). This positive
effect of the double bond in the linker was not valid for the indole-
amide and the naphthalene-oxadiazole series, because 25, 26, 44,
and 45 were inactive in the three enzymatic assays. Surprisingly,
the introduction of a propargyl substituent in the oxadiazolone ring
of the MAO-A/B inhibitor 23 to give 24 led to a total lack of activity
on these enzymes (data not shown). Contrariwise, the
dihydronaphthalene-oxadiazolone 33 inhibited hMAO-A, hMAO-B
and hLOX-5 with IC50 values of 40.6, 35.7 and 12.5 mM, respectively
(Table 2).2.7. In vitro bloodbrain barrier permeation assay (PAMPA-BBB)
In order to determine the capability of the new compounds to
cross the BBB and reach their CNS targets, we evaluated them in the
in vitro parallel artificial membrane permeability assay for the BBB
(PAMPA-BBB) described by Di et al. [52], and modified by our group
for testing molecules with limited water solubility [44e46,53,54].
The passive CNS permeation of new compounds through a lipidTable 2
Inhibition (IC50, mM)a of human monoamine oxidases (hMAO-A and hMAO-B) and
human lipoxygenase-5 (hLOX-5) of indole and naphthalene derivativesb.
Compd. hMAO-A hMAO-B hLOX-5
12 >50 >50 74.2 ± 2.2
13 >50 >50 22.5 ± 1.8
16 >50 37.0 ± 0.7 60.6 ± 2.6
23 53.0 ± 3.5 68.3 ± 4.6 >100
33 40.6 ± 1.1 35.7 ± 3.3 12.5 ± 0.3
(R)-Deprenyl 68.7 ± 4.2 0.017 ± 0.002 n.d.
Iproniazid 6.7 ± 0.8 7.5 ± 0.4 n.d.
Moclobemide 161.4 ± 19.4 >100 n.d.
(R,S)-Zileuton n.d. n.d. 0.15 ± 0.03
NDGA n.d. n.d. 0.097 ± 0.019
a Data are the mean ± SD of three independent experiments performed in
triplicate.
b Data of inactive compounds in the three enzymes are not shown.
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experiment, 11 commercial drugs of known brain permeability
were also tested, and their permeability values were normalized to
the reported PAMPA-BBB data. As previously established in the
literature [52], compounds with Pe > 4.0$106 cm s1 would be able
to cross the BBB (cnsþ), whereas those displaying
Pe < 2.0$106 cm s1 would not reach the CNS (cns-). Between these
values, the predicted CNS permeability remains uncertain (cns þ/
).
In the melatonin-based family, the indoleeNH-oxadiazolone 1
and its beta-methyl analogue 21 (both bearing a saturated linker)
were predicted as not CNS-permeable (Pe < 2$106 cm s1). In
contrast, all indoleeN-substituted oxadiazolone derivatives (2e15),
showed permeability values exceeding 4.0 106 cm s1 and thus,
they were predicted to be CNS-permeable. The
indoleeoxadiazolamine 16 displayed negative CNS permeation,
whereas the indoleeNH-oxadiazolone 23, which is the unsaturated
analogue of 1, displayed a permeability value in the ambiguous
range (Pe ¼ 3.2$106 cm s1). The attachment of a propargylic
moiety onto the oxadiazolone ring nitrogen of 23 gave 24, which
-as expected-was found to be CNS-permeable. Unsaturated amides
25 and 26 showed negative CNS permeability.
The exchange of the indole heterocycle by a dihydronaph-
thalene (33) or a naphthalene (44 and 45) generated compounds
with good CNS permeability values (Pe ¼ 9.0, 9.8 and 4.5
106 cm s1, respectively), even when the NH-unsubstituted oxa-
diazolone ring was retained. From these experiments we can
conclude that, in general, the new indole and naphthalene de-
rivatives with a single NH-unsubstituted motif are expected to be
CNS-penetrating, whereas compounds with two NH groups would
experience more difficulties to reach the CNS.2.8. Drug-like calculations
To choose the best candidates for neurogenic assays, we studied
the medicinal chemistry alerts of new indole- or naphthalene-
oxadiazolones in two free databases, namely ZINC15 (http://
zinc15.docking.org/) [55] and Aggregator Advisor (http://advisor.
bkslab.org/) [56] (Table S2 in the Supplementary Information).
None of the new compounds was highlighted as a pan assay
interference compound (PAINS), according to the ZINC15 database.
However, the Aggregator Advisor website identified compounds 13
and 15 with a fairly high calculated LogP in the range reported for
other aggregators. Thus, these compounds were discarded for
further biological assays.
Moreover, we calculated several physicochemical and ADME
properties (log P, solubility, pKa and Lipinski rule) of selected
compounds (23, 24 and 44) in comparisonwithmelatonin (Table S3
in the Supplementary Information). According to the Swiss Insti-
tute of Bioinformatics (http://www.swissadme.ch/) [57], these
compounds showed a good drug-like profile and thus, they are
good candidates for further pharmacological studies.2.9. Neurogenic studies
We investigated the capacity of a selection of the new com-
pounds, covering different structural features, to promote cell dif-
ferentiation into neurons. To this end, hippocampal-derived
neurospheres adhered to a substrate and cultured under differen-
tiation conditions in the presence of compounds were used [27,58].
The neurogenic potential of each compound was determined using
fluorescence confocal microscopy, by direct observation of the
expression of two immunofluorescent dyes linked to two well-known neuronal markers, bIII-tubulin (TuJ-1 clone) shown in
green andmicrotubule-associated protein 2 (MAP-2) in red. TuJ-1 is
expressed in new born neurons in early stages of their differenti-
ation, whereas the expression of MAP-2 indicates a consolidated
neuronal stage [59]. Vehicle-treated cultures (considered as basal)
showed only a few scattered positive TuJ-1 or MAP-2 cells. In
contrast, treatment with the compounds resulted in an increase in
the number of TuJ-1 and MAP-2-positive cells compared to basal
levels.
In themelatonin-based family several compounds promoted the
expression of TuJ-1 and MAP-2, indicating positive neurogenic ac-
tivities (Fig. 3). Comparing derivatives with a dimethylene liker, the
indoleeoxadiazolone 4 displayed good neurogenic properties,
whereas its indoleeoxadiazolamine counterpart 16 was inactive.
This result points out the importance of the presence of an oxa-
diazolone ring for successful neurogenesis.
Among indole compounds bearing a double bond in the linker,
the indoleeN-propargyloxadiazolone 24was one of the most active
derivatives, as it greatly increased the expression of both TuJ-1 and
MAP-2. Conversely, its indoleeNH-oxadiazolone analogue 23 was
inactive, suggesting that the N-propargyl group is beneficial for
activity.
Both naphthaleneeNH-oxadiazolone derivatives 44 and 45
showed positive effects in the expression of TuJ-1 and MAP-2. In
contrast, the dihydronaphthalene analogue 33 was inactive, sug-
gesting that the naphthalene core is more useful for biasing the
compounds towards neurogenesis.2.10. Theoretical studies. Conformational analysis of indole and
naphthalene derivatives 23 and 44
As explained above, the indoleeNH-oxadiazolone derivative 23
showed marked selectivity towards QR2 (Ki ¼ 6.6 nM), in com-
parison with hMT1R and hMT2R (Ki > 100 nM). In contrast, substi-
tution of a naphthalene ring for the indole heterocycle gave 44,
which was a potent and selective agonist at hMT2R (EC50 ¼ 1.1 nM),
compared to hMT1R and QR2 (Ki ¼ 260 and 270 nM, respectively)
(Table 1).
With the aim of explaining this distinct behaviour in NH-oxa-
diazolone derivatives that only differ in the nature of the fused
heterocycle, we performed a conformational analysis of 23 and 44
using quantum mechanics (Fig. 4).
The conformational analysis revealed higher energy barriers
(~2 kcal mol1) for rotation about the C2eC3 bond and a preferred
flat conformation in the indoleeNH-oxadiazolone 23 (Fig. 4). This
co-planar arrangement of the ring systems is prevented in the
naphthalene derivative 44 due to steric clash as a consequence of
the decreased C1eC2eC3 angle. These results seemed to indicate
that the flat conformation of 23 might favour the stacking inter-
actionwith the isoalloxazine ring of FAD in QR2, whereas the slight
non-planarity of 44 (dihedral angle of ~40) would be preferred for
its agonist activity on hMT2R. On the other hand, the energy bar-
riers for rotation about the C4eC5 bond are of similar magnitude in
both molecules.2.11. Molecular dynamics simulations on hQR2, hMT1R and hMT2R
To test the previous hypotheses, we undertook some molecular
dynamics studies. In agreement with the previous statement, our
modelled complexes of hQR2 (Fig. 5) and hMT2R (Fig. 6) with 23
and 44, respectively, show that the proposed stacking of the flat 23
molecule on FAD is reminiscent of that described for resveratrol
[60], with the indole nitrogen establishing a hydrogen bond to the
Fig. 3. Melatonin-based compounds promote neuronal differentiation on SGZ-derived neurospheres. Neurospheres were cultured in the presence of compounds (10 mM) for 7 days
and later adhered for 3 days to allow differentiation in the presence of compounds. Confocal images show the expression of the neuronal markers TuJ clone (early neurogenesis) in
green and MAP-2 (mature neurons) in red. DAPI was used for nuclear staining. Fluorescent representative images from four independent experiments were displayed. Scale
bar ¼ 100 mm (images of inactive compounds are not shown). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this
article.)
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the resorcinol hydroxyls of this naturally occurring polyphenol. It
can also be seen that the oxadiazolone nitrogen is engaged in
hydrogen bonds to water molecules, which would be displaced
when the attached hydrogen is replaced with a short substituent, as
is the case for the propargyl group present in 24 (Fig. S1, Supporting
Information).
In contrast, for the less coplanar naphthalene derivatives, the
variety of binding orientations we found is commensurate with
that observed in X-ray crystal structures of QR2 in complex with
melatonin and derivatives [61]. Nonetheless, the out-of-plane
conformation of 44 is ideally suited to mimic the bound confor-
mation of melatonin that has been observed in the XFEL structures
of chimeric MT1R and MT2R constructs, very recently described by
Stauch et al. [62] and Johansson et al. [63], respectively. At this
location in our modelledMT2R, binding of 44 is largely stabilized by
the phenyl ring of Phe192ECL2, additional hydrophobic interactions
with neighbouring residues (including the highly conserved
Trp2646.48 that was replaced by Phe in the experimental con-
structs) and a number of direct and water-mediated hydrogen
bonds with the polar side chains of Gln194ECL2, Asn1624.60, and
Asn2686.52. The most important difference relative to MT1R is the
orientation of Tyr2005.38, which is close to the side chains of Val178
ECL2 and Ser180 ECL2 and whose phenolic group hydrogen bonds to
the carbonyl oxygen of Ala1714.56. In MT1R, the equivalent residues
are Ala165 ECL2 and Thr167 ECL2 so that the side chain of Tyr1875.38points towards the membrane [62,63] and slightly different in-
teractions are observed (Fig. S2, Supporting Information).
2.12. Molecular docking studies and molecular dynamics
simulations on KEAP1
Molecular docking studies of 23 and 24were performed on four
different crystal structures of the KEAP1 Kelch domain (PDB entries
4XMB, 5CGJ, 5FNU and 4IFL) to consider, at least partially, protein
flexibility. At physiologic pH, compound 23 exists as two different
species, as deduced from its experimental pKa of 7.45± 0.09 (Fig. S3,
Supporting Information). No substantial differences in the average
binding energy values were observed in both species, named 23-
0 and 23-1. On the other hand, the higher affinity score obtained for
24 correlated with the experimental NRF2 induction value in the
AREc32 cell line (Table S1, Supporting Information).
Themost stable molecular docking poses found for 23 and 24 on
the four 3D-structures of the KEAP1 Kelch domain (Figs. S4 and S5,
Supporting Information) were used as the starting structures for
uMD simulations, which after 200 ns of production run showed
some drifting of the bound ligand towards a new ligand-protein
interface (Fig. 7). The binding site residues involved in the NRF2-
KEAP1 interaction are very well known and have been reported
by several authors [64]. It has been shown that residues
Arg380,415,483; Ser363,508,555,602; and Tyr525,572,334 on
KEAP1 are essential to interact with NRF2. Our uMD simulations
Fig. 4. Global energy conformations of indoleeNH-oxadiazolone 23 (A) and naphthaleneeNH-oxadiazolone 44 representative molecules (B), together with the rotational barriers
(in vacuum, blue; using an implicit solvent model for water, orange) upon rotation about the bonds connecting atoms labelled 2 and 3 (top) and 4 and 5 (bottom). (For interpretation
of the references to color in this figure legend, the reader is referred to the Web version of this article.)
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and also 23 experiences greater fluctuations within the binding
pocket in KEAP1. This difference mostly arises from the fact that 24
interacts with hydrophobic residues Phe577 and Ala556 whereas
23 does not.
Finally, thermodynamic calculations over the last 10 ns of theproduction run, using the Molecular Mechanics Generalized Born
Surface Area approach (MMGBSA) [65], revealed a noticeably
higher affinity for 24 relative to 23 that is in consonance with the
experimental finding that 24 leads to a larger activation and
expression of NRF2 in AREc32 cells (Table 1).
Fig. 5. Representative models of hQR2 in complex with indole e NH-oxadiazolone derivative 23 (sticks with C atoms coloured in grey) obtained after the simulated annealing
procedure following molecular dynamics simulations. The starting reference structure was PDB entry 1SG0.
Fig. 6. Model of a membrane-embedded hMT2R (rainbow coloured) in complex with naphthaleneeNH-oxadiazolone derivative 44 (sticks with C atoms coloured in grey). The
enlarged region in the box shows the superposition of eight cooled and energy-minimized snapshots from the last 170e200 ns of unrestrained molecular dynamics (uMD)
simulation. The starting reference structure was PDB entry 6ME8.
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Fig. 7. Dynamic conformation of KEAP1-ligand complexes. A) KEAP1-23 complex. B) KEAP1-24 complex. Water molecules and ions are not depicted for clarity. KEAP1 is represented
as a brown molecular surface [66]. Residues involved into protein-ligand interaction are represented as sticks by colour type: green are polar residues, blue are positive charged
residues and white are hydrophobic residues. Ligands are represented as sticks with grey carbon atoms, blue nitrogen atoms, red oxygen atoms and white hydrogen atoms. Thinner
white sticks correspond to the ligand conformations during the last 10ns of the MD production. These images were made with VMD software support [67]. The most stable
molecular docking poses found for 23 and 24 on the 3D-structures of the KEAP1 Kelch domain with pdbcode 4XMB were used as the starting reference structure. (For interpretation
of the references to color in this figure legend, the reader is referred to the Web version of this article.)
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By structural modifications of our described hMT1R and hMT2R
nanomolar ligand 5-[2-(5-methoxy-1H-indol-3-yl)ethyl]-1,3,4-
oxadiazol-2(3H)-one (1), new indolee and
naphthaleneeoxadiazolone MTDLs have been obtained and eval-
uated on targets related to oxidative stress and neuroinflammation.
Introduction of lipophilic substituents on the nitrogen of the oxa-
diazolone ring improved their in vitro CNS permeation but was
detrimental for their affinity for the GPCRs hMT1R and hMT2R. The
addition of a methyl group in the aliphatic linker of 1 or the
replacement of the oxadiazolone ring by a 1,3,4-oxadiazol-2-amine
scaffold yielded compounds with Kis in the hundred-nanomolar
range in melatonin targets, but they were predicted as not CNS-
permeable.
Introduction of a double bond in the linker provided interesting
effects on the behaviour of these less flexible indole- and
naphthalene-oxadiazolone compounds. The 5-methoxyindole de-
rivatives 23 and 24 displayed remarkable selectivity towards QR2
(Ki ¼ 6.6 and 3.2 nM, respectively) in reference to hMT1R and
hMT2R (Kis > 100 nM). In contrast, when the 5-methoxyindole of 23
was replaced by a 7-methoxynaphthalene the selectivity changed
drastically, since 44 was preferably bound to hMT2R (Ki ¼ 5.1 nM)
compared to hMT1R and QR2 (Ki ¼ 260 and 270 nM, respectively).
Moreover, 44 was functionally characterized as a potent hMT2R
agonist with a maximum activity of 85% with respect to melatonin
and an EC50 of 1.1 nM.
Conformational analyses using quantum mechanics revealed
that the indole-NH-oxadiazolone 23 presents a co-planar arrange-
ment of the ring systems, whereas the naphthalene-NH-oxadia-
zolone 44 shows a dihedral angle of ~40 between both
heterocycles. These differences could explain the observed selec-
tivity of 23 and 44 towards QR2 and hMT2R, respectively. Molecular
modelling and computer simulations, using the crystal structure of
QR2 and the recently described XFEL structures of chimeric MT1R
and MT2R, have provided a rationale for the experimental selec-
tivity and afford valuable insight that can aid in future drug design
endeavours.
In the ORAC assays, indole derivatives were found to be as goodradical scavengers as melatonin, whereas naphthalene-based
compounds showed worse ORAC values. Thus, the radical absor-
bance capacity was mainly linked to the indole ring.
In relation to NRF2 induction, best results were obtained with
the indoleeNH-oxadiazolone derivative with a double bond in the
linker 23 and its N-propargylic counterpart 24 (CD ¼ 15.1 and
1.8 mM, respectively). When comparing with other derivatives, we
can infer the importance of the presence of the indole core and a
double bond in the connector to achieve a good induction of NRF2.
From the SPR experiments using the KEAP1 Kelch domain, we could
infer that the cellular NRF2 induction by compounds 23 and 24
could be due to the binding of these molecules to KEAP1. Moreover,
molecular dynamics simulations on the KEAP1 Kelch domain
showed that 23 and 24 interact with several essential residues
involved in the binding KEAP1-NRF2. Thermodynamic calculations
revealed higher affinity for 24 than for 23, according to the
experimental finding that 24 leads to a larger activation and
expression of NRF2 in cellular experiments.
Several saturated indoleeoxadiazolone derivatives weremodest
hLOX-5 inhibitors and inactive in hMAOs. However, the introduc-
tion of a double bond in the linker again reversed selectivity, as the
indoleeNH-oxadiazolone 23 inhibited hMAOs but it is inactive in
hLOX-5. Only the dihydronaphthalene-oxadiazolone 33 was found
to inhibit the three enzymes, with IC50 values in the two-digit
micromolar range.
In neurogenic assays, several of the new melatonin-
oxadiazolone derivatives stimulated the differentiation of NSC to
a consolidated neuronal stage, as they could contribute to the auto-
repair processes of the CNS.
Finally, it can be emphasized that it is possible to modulate the
selectivity of these new oxadiazolone-based MTDLs by modifying
the side chain functionality and co-planarity with the indole or
naphthalene ring.4. Experimental section
4.1. Chemistry. General methods
High-grade reagents and solvents were purchased from
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Reactions were followed by thin-layer chromatography (TLC) or
high-performance liquid chromatography coupled to mass spec-
trometry (HPLC-MS). TLC was performed using Merck silica gel 60
F254 plates and compounds were detected under UV-light (l¼ 254
or 365 nm) and/or stained with 10% wt. phosphomolybdic acid,
ninhydrin, or vanillin solutions in EtOH. HPLC-MS data were ac-
quired in an Alliance Watters 2695 coupled to a quadrupole mass
spectrometer (Micromass ZQ). HPLC was equipped with a SunFire
C18 column (3.5 mm, 4.6 mm  50 mm) and a UVevisible photo-
diode array detector (l ¼ 190e700 nm). MS were acquired in an
electrospray ionization (ESI) interface working in the positive or
negative-ion mode. Microwave driven reactions were performed in
a Biotage Initiator 2.5 reactor. Unless otherwise stated, products
were purified by automatized flash column chromatography using
an IsoleraOne (Biotage) equipment, with different cartridges of
silica gel Biotage ZIP KP-Sil 50 mm. Alternatively, we used prepar-
ative TLC on Merck silica gel 60 F254 plates or semipreparative
HPLC on a Waters Autopurification system with UVevisible
photodiode array detector (l ¼ 190e700 nm) coupled to a quad-
rupole mass spectrometer (3100 Mass Detector). Purity of all
compounds (95%) was determined by HPLC on a Waters 2690
equipment, at a flow rate of 1.0 mL/min, with a UVevisible
photodiode array detector (l ¼ 190e700 nm), using a SunFire C18
column (3.5 mm, 4.6 mm  50 mm). The gradient of the mobile
phase consisted of H2O:ACN with formic acid (0.1%), and the gra-
dients time (g.t.) are indicated for each compound. Melting points
(mp) (uncorrected) were determined in a MP70 apparatus (Mettler
Toledo). Nuclear magnetic resonance (1H NMR and 13C NMR)
spectra were obtained in the following spectrometers: Varian
INOVA-300, Varian INOVA-400, Varian Mercury-400 or Varian
Unity-500. Chemical shifts (d) are reported in parts per million
(ppm) relative to internal tetramethylsilane scale, and coupling
constants (J) are expressed in hertz (Hz). 2D NMR experiments
namely, homonuclear correlation spectroscopy (H,HeCOSY), het-
eronuclear multiple quantum correlation (HMQC) and hetero-
nuclear multiple bond correlation (HMBC) were acquired to assign
protons and carbons of new structures. High resolution mass
spectra (HRMS) analyses were carried out by using an Agilent 1200
Series LC system (equipped with a binary pump, an autosampler,
and a column oven) coupled to a 6520 quadrupole-time of flight
(QTOF) mass spectrometer. ACN:H2O (75:25, v:v) was used as
mobile phase at 0.2 mL/min. The ionization source was an ESI
interface working in the positive-ion mode. The electrospray
voltage was set at 4.5 kV, the fragmentary voltage at 150 V and the
drying gas temperature at 300 C. Nitrogen (99.5% purity) was used
as nebulizer (207 kPa) and drying gas (6 L/min).
4.2. General procedure for the synthesis of 2e15
A mixture of 1 (1 equiv.), K2CO3 (1.2 equiv.) and the corre-
sponding halide (1.2 equiv) in acetone (7 mL/mmol) was heated
under MW-irradiation at 120 C for 10 min. Solvent was evaporated
under reduced pressure, EtOAc (10 mL/mmol) was added and the
organic layer was washed with H2O (x3) and brine and then, dried
over MgSO4, filtered, and evaporated to dryness under reduced
pressure. The crude was purified by column chromatography using
the appropriate eluent to afford the corresponding alkyl derivative
2e15.
4.3. Characterization of compounds 2e45
4.3.1. 5-[2-(5-Methoxy-1H-indol-3-yl)ethyl]-3-methyl-1,3,4-
oxadiazol-2(3H)-one (2)
Chromatography: DCM to DCM:MeOH 95:5. White solid (66%yield) of mp 83e86 C. 1H NMR (500 MHz, CDCl3) d 7.97 (s, 1H, NH),
7.25 (d, J ¼ 8.6 Hz, 1H, H7), 7.00 (d, J ¼ 2.5 Hz, 1H, H2), 6.99 (d,
J ¼ 2.4 Hz, 1H, H4), 6.87 (dd, J ¼ 8.7, 2.4 Hz, 1H, H6), 3.87 (s, 3H,
OCH3), 3.35 (s, 3H, NCH3), 3.12 (t, J ¼ 7.7 Hz, 2H, Ha), 2.92 (t,
J ¼ 7.7 Hz, 2H, Hb). 13C NMR (126 MHz, CDCl3) d 155.9 (C5’), 154.4
(C2’), 154.2 (C5), 131.5 (C7a), 127.4 (C3a), 122.5 (C2), 113.6 (C3), 112.6
(C6), 112.2 (C7), 100.3 (C4), 56.1 (OCH3), 32.5 (NCH3), 27.4 (Cb), 21.5
(Ca). HPLC-MS (15:95- g.t.5 min) tR 3.97 min,m/z¼ 274.20 [MþH]þ,
calcd. for [C14H15N3O3þH]þ 274.29. HRMS [ESIþ] m/z ¼ 273.11145
[M]þ, calcd. for [C14H15N3O3]þ 273.11134.
4.3.2. 3-Ethyl-5-[2-(5-methoxy-1H-indol-3-yl)ethyl]-1,3,4-
oxadiazol-2(3H)-one (3)
Chromatography: DCM to DCM:MeOH 95:5. White solid (56%
yield) of mp 69e72 C. 1H NMR (500 MHz, CDCl3) d 7.90 (s, 1H, NH),
7.26 (d, J ¼ 8.8 Hz, 1H, H7), 7.01 (d, J ¼ 2.5 Hz, 1H, H2), 6.99 (d,
J ¼ 2.3 Hz, 1H, H4), 6.87 (dd, J ¼ 8.8, 2.4 Hz, 1H, H6), 3.87 (s, 3H,
OCH3), 3.71 (q, J ¼ 7.2 Hz, 2H, CH2CH3), 3.15e3.11 (m, 2H, Ha),
2.95e2.90 (m, 2H, Hb), 1.28 (t, J ¼ 7.2 Hz, 3H, CH2CH3). 13C NMR
(126 MHz, CDCl3) d 155.9 (C5’), 154.3 (C5), 154.0 (C2’), 131.5 (C7a),
127.5 (C3a), 122.5 (C2), 113.8 (C3), 112.7 (C6), 112.1 (C7), 100.3 (C4),
56.1 (OCH3), 40.8 (CH2CH3), 27.6 (Cb), 21.6 (Ca), 13.5 (CH2CH3).
HPLC-MS (15:95- g.t.5 min) tR 4.21 min, m/z ¼ 288.15 [MþH]þ,
calcd. for [C15H17N3O3þH]þ 288.32. HRMS [ESIþ] m/z ¼ 287.1275
[M]þ, calcd. for [C15H17N3O3]þ 287.12699.
4.3.3. 5-[2-(5-Methoxy-1H-indol-3-yl)ethyl]-3-propyl-1,3,4-
oxadiazol-2(3H)-one (4)
Chromatography: DCM to DCM:MeOH 95:5. White solid (49%
yield) of mp 95e98 C. 1H NMR (500 MHz, DMSO‑d6) d 10.67 (s, 1H,
NH), 7.21 (dd, J¼ 8.7, 0.5 Hz, 1H, H7), 7.11 (d, J¼ 2.5 Hz, 1H, H2), 6.97
(d, J ¼ 2.4 Hz, 1H, H4), 6.70 (dd, J ¼ 8.8, 2.4 Hz, 1H, H6), 3.75 (s, 3H,
OCH3), 3.53 (t, J¼ 6.8 Hz, 2H, NCH2), 3.00 (t, J¼ 7.4 Hz, 2H, Ha), 2.90
(t, J ¼ 7.5 Hz, 2H, Hb), 1.57 (h, J ¼ 7.2 Hz, 2H, CH2CH3), 0.78 (t,
J ¼ 7.4 Hz, 3H, CH2CH3). 13C NMR (126 MHz, DMSO‑d6) d 155.6 (C5’),
153.5 (C2’), 153.0 (C5), 131.3 (C7a), 127.1 (C3a), 123.3 (C2), 112.1 (C7),
111.9 (C3), 111.2 (C6), 99.7 (C4), 55.3 (OCH3), 46.4 (NCH2), 26.9 (Cb),
21.0 (CH2CH3), 20.8 (Ca), 10.6 (CH2CH3). HPLC-MS (15:95- g.t.5 min)
tR 4.48 min, m/z ¼ 302.28 [MþH]þ, calcd. for [C16H19N3O3þH]þ




Chromatography: DCM.White solid (92% yield) of mp 64e65 C.
1H NMR (500 MHz, DMSO‑d6) d 10.67 (s, 1H, NH), 7.21 (d, J¼ 8.7 Hz,
1H, H7), 7.10 (d, J ¼ 2.4 Hz, 1H, H2), 6.96 (d, J ¼ 2.5 Hz, 1H, H4), 6.70
(dd, J¼ 8.7, 2.4 Hz,1H, H6), 3.75 (s, 3H, OCH3), 3.55 (t, J¼ 6.9 Hz, 2H,
NCH2), 3.00 (t, J ¼ 7.4 Hz, 2H, Ha), 2.91 (t, J ¼ 7.5 Hz, 2H, Hb), 1.52 (p,
J ¼ 7.0 Hz, 2H, NCH2CH2), 1.17 (h, J ¼ 7.4 Hz, 2H, CH2CH3), 0.83 (t,
J ¼ 7.4 Hz, 3H, CH2CH3). 13C NMR (126 MHz, DMSO‑d6) d 155.6 (C5’),
153.4 (C2’), 153.0 (C5), 131.3 (C7a), 127.1 (C3a), 123.3 (C2), 112.1 (C7),
111.9 (C3), 111.2 (C6), 99.7 (C4), 55.3 (OCH3), 44.4 (NCH2), 29.5
(NCH2CH2), 26.9 (Cb), 20.8 (Ca), 18.8 (CH2CH3), 13.3 (CH2CH3). HPLC-
MS (15:95- g.t.5 min) tR 4.79 min, m/z ¼ 316.11 [MþH]þ, calcd. for




Chromatography: DCM. Pale yellow solid (90% yield) of mp
48e51 C. 1H NMR (500 MHz, CDCl3) d 7.90 (s, 1H, NH), 7.25 (d,
J¼ 8.5 Hz, 1H, H7), 7.01 (d, J¼ 2.5 Hz, 1H, H2), 6.99 (d, J¼ 2.4 Hz, 1H,
H4), 6.87 (dd, J ¼ 8.8, 2.5 Hz, 1H, H6), 3.87 (s, 3H, OCH3), 3.63 (t,
J ¼ 7.2 Hz, 2H, NCH2), 3.13 (t, J ¼ 7.4 Hz, 2H, Ha), 2.92 (t, J ¼ 7.5 Hz,
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CH2CH3), 1.30e1.21 (m, 2H, N(CH2)2CH2), 0.89 (t, J ¼ 7.2 Hz, 3H,
CH2CH3). 13C NMR (126 MHz, CDCl3) d 155.8 (C5’), 154.3 (C5), 154.3
(C2’), 131.5 (C7a), 127.5 (C3a), 122.5 (C2), 113.7 (C3), 112.7 (C6), 112.1
(C7), 100.3 (C4), 56.1 (OCH3), 45.8 (NCH2), 28.6 (N(CH2)2CH2), 27.9
(NCH2CH2), 27.6 (Cb), 22.3 (CH2CH3), 21.6 (Ca), 14.1 (CH2CH3). HPLC-
MS (30:95- g.t.5 min) tR 4.60 min, (50:95- g.t.5 min) tR 3.17 min,m/
z ¼ 330.13 [MþH]þ, calcd. for [C18H23N3O3þH]þ 330.40. HRMS
[ESIþ] m/z ¼ 329.17515 [M]þ, calcd. for [C18H23N3O3]þ 329.17394.
4.3.6. 3-Hexyl-5-[2-(5-methoxy-1H-indol-3-yl)ethyl]-1,3,4-
oxadiazol-2(3H)-one (7)
Chromatography: hexane to DCM. Colorless oil (70% yield). 1H
NMR (500 MHz, MeOD) d 7.20 (d, J ¼ 8.7 Hz, 1H, H7), 7.03 (bs, 1H,
H2), 6.95 (d, J¼ 2.4 Hz, 1H, H4), 6.74 (dd, J¼ 8.8, 2.4 Hz, 1H, H6), 3.82
(s, 3H, OCH3), 3.57 (t, J ¼ 6.9 Hz, 2H, NCH2), 3.11 (t, J ¼ 7.2 Hz, 2H,
Ha), 2.92 (t, J ¼ 7.2 Hz, 2H, Hb), 1.56 (p, J ¼ 7.0 Hz, 2H, NCH2CH2),
1.30e1.21 (m, 4H, N(CH2)3(CH2)2CH3), 1.20e1.10 (m, 2H,
N(CH2)2CH2), 0.88 (t, J ¼ 6.9 Hz, 3H, CH2CH3). 13C NMR (126 MHz,
MeOD) d 157.6 (C5’), 156.0 (C2’), 155.1 (C5), 133.3 (C7a), 128.7 (C3a),
124.1 (C2), 113.6 (C3), 113.0 (C7), 112.8 (C6), 100.7 (C4), 56.2 (OCH3),
46.4 (NCH2), 32.3 (N(CH2)3CH2), 28.9 (NCH2CH2), 28.7 (Cb), 26.9
(N(CH2)2CH2), 23.5 (CH2CH3), 22.4 (Ca), 14.3 (CH2CH3). HPLC-MS
(50:95- g.t.5 min) tR 3.77 min, m/z ¼ 344.38 [MþH]þ, calcd. for
[C19H25N3O3þH]þ 344.43. HRMS [ESIþ] m/z ¼ 343.18957 [M]þ,
calcd. for [C19H25N3O3]þ 343.18959.
4.3.7. 3-Heptyl-5-[2-(5-methoxy-1H-indol-3-yl)ethyl]-1,3,4-
oxadiazol-2(3H)-one (8)
Chromatography: hexane to DCM. Yellow oil (85% yield). 1H
NMR (300MHz, CDCl3) d 7.95 (s, 1H, NH), 7.25 (d, J¼ 8.9 Hz,1H, H7),
7.02e6.95 (m, 2H, H2, H4), 6.86 (dd, J ¼ 8.8, 2.4 Hz, 1H, H6), 3.87 (s,
3H, OCH3), 3.63 (t, J¼ 7.2 Hz, 2H, NCH2), 3.13 (dd, J¼ 8.6, 6.3 Hz, 2H,
Ha), 2.92 (dd, J ¼ 8.6, 6.4 Hz, 2H, Hb), 1.67 (p, J ¼ 7.3 Hz, 2H,
NCH2CH2), 1.34e1.19 (m, 8H, N(CH2)2(CH2)4CH3), 0.88 (t, J ¼ 6.7 Hz,
3H, CH2CH3). 13C NMR (75 MHz, CDCl3) d 155.9 (C5’), 154.3 (C5),
154.3 (C2’), 131.5 (C7a), 127.5 (C3a), 122.5 (C2), 113.7 (C3), 112.6 (C6),
112.1 (C7), 100.3 (C4), 56.1 (OCH3), 45.8 (NCH2), 31.8 (N(CH2)4CH2),
28.9 (N(CH2)3CH2), 28.2 (NCH2CH2), 27.6 (Cb), 26.4 (N(CH2)2CH2),
22.7 (CH2CH3), 21.6 (Ca), 14.2 (CH2CH3). HPLC-MS (70:95- g.t.5 min)
tR 1.56 min, m/z ¼ 358.25 [MþH]þ, calcd. for [C20H27N3O3þH]þ




Chromatography: DCM. White solid (81% yield) of mp
130e133 C. 1H NMR (500 MHz, CDCl3) d 7.88 (bs, 1H, NH), 7.25 (d,
J¼ 7.8 Hz, 1H, H7), 7.01 (d, J ¼ 2.4 Hz, 1H, H2), 6.99 (d, J¼ 2.4 Hz, 1H,
H4), 6.86 (dd, J ¼ 8.8, 2.4 Hz, 1H, H6), 4.25e4.21 (m, 1H, CH(CH3)2),
3.87 (s, 3H, OCH3), 3.13 (dd, J ¼ 7.6 Hz, 2H, Ha), 2.92 (dd, J ¼ 7.7 Hz,
2H, Hb), 1.30 (d, J ¼ 6.7 Hz, 6H, CH(CH3)2). 13C NMR (126 MHz,
CDCl3) d 155.8 (C5’), 154.3 (C5), 153.6 (C2’), 131.5 (C7a), 127.6 (C3a),
122.5 (C2), 113.9 (C3), 112.7 (C6), 112.1 (C7), 100.3 (C4), 56.1 (OCH3),
47.9 (CH(CH3)2), 27.7 (Cb), 21.6 (Ca), 20.8 (CH(CH3)2). HPLC-MS
(15:95- g.t.5 min) tR 4.49 min, m/z ¼ 302.35 [MþH]þ, calcd. for
[C16H19N3O3þH]þ 302.35. HRMS [ESIþ] m/z ¼ 301.14244 [M]þ,
calcd. for [C16H19N3O3]þ 301.14264.
4.3.9. 5-[2-(5-Methoxy-1H-indol-3-yl)ethyl]-3-(2-methylpropyl)-
1,3,4-oxadiazol-2(3H)-one (10)
Chromatography: DCM.White solid (82% yield) of mp 54e56 C.
1H NMR (500 MHz, DMSO‑d6) d 10.67 (s, 1H, NH), 7.21 (d, J¼ 8.7 Hz,
1H, H7), 7.10 (d, J ¼ 2.4 Hz, 1H, H2), 6.97 (d, J ¼ 2.4 Hz, 1H, H4), 6.70
(dd, J¼ 8.7, 2.4 Hz,1H, H6), 3.75 (s, 3H, OCH3), 3.37 (d, J¼ 7.1 Hz, 2H,NCH2), 3.00 (t, J ¼ 7.3 Hz, 2H, Ha), 2.91 (t, J ¼ 7.2 Hz, 2H, Hb),
1.90e1.87 (m, 1H, CH(CH3)2), 0.79 (d, J ¼ 6.7 Hz, 6H, CH(CH3)2). 13C
NMR (126 MHz, DMSO‑d6) d 155.6 (C5’), 153.7 (C2’), 153.0 (C5), 131.3
(C7a), 127.1 (C3a), 123.3 (C2), 112.1 (C7), 111.9 (C3), 111.2 (C6), 99.7 (C4),
55.3 (OCH3), 51.8 (NCH2), 27.4 (CH(CH3)2), 26.9 (Cb), 20.8 (Ca), 19.4
(CH(CH3)2). HPLC-MS (15:95- g.t.5 min) tR 4.77 min, m/z ¼ 316.34
[MþH]þ, calcd. for [C17H21N3O3þH]þ 316.37. HRMS [ESIþ] m/
z ¼ 315.15958 [M]þ, calcd. for [C17H21N3O3]þ 315.15829.
4.3.10. 3-(Cyclopropylmethyl)-5-[2-(5-methoxy-1H-indol-3-yl)
ethyl]-1,3,4-oxadiazol-2(3H)-one (11)
Chromatography: DCM.White solid (88% yield) of mp 94e97 C.
1H NMR (500 MHz, CDCl3) d 7.89 (s, 1H, NH), 7.26 (d, J ¼ 8.8 Hz, 1H,
H7), 7.02 (d, J ¼ 2.4 Hz, 1H, H2), 7.00 (d, J ¼ 2.7 Hz, 1H, H4), 6.87 (dd,
J ¼ 8.8, 2.4 Hz, 1H, H6), 3.87 (s, 3H, CH3), 3.52 (d, J ¼ 7.2 Hz, 2H,
NCH2), 3.13 (q, J ¼ 7.0 Hz, 2H, Ha), 2.96e2.90 (m, 2H, Hb), 1.19e1.09
(m, 1H, CH(CH2)2), 0.57e0.51 (m, 2H, CH(CH2)2), 0.34 (dt, J ¼ 6.2,
4.8 Hz, 2H, CH(CH2)2). 13C NMR (126MHz, CDCl3) d 155.9 (C2’), 155.8
(C5’), 154.3 (C5), 131.5 (C7a), 127.5 (C3a), 122.5 (C2), 113.8 (C3), 112.7
(C6), 112.1 (C7), 100.3 (C4), 56.1 (CH3), 50.5 (NCH2), 27.5 (Cb), 21.6
(Ca), 10.0 (CH(CH2)2), 3.6 (CH(CH2)2). HPLC-MS (15:95- g.t.5 min) tR
4.57min,m/z¼ 314.03 [MþH]þ, calcd. for [C17H19N3O3þH]þ 314.36.




Chromatography: hexane to DCM. Pale yellow solid (75% yield)
of mp 74e76 C. 1H NMR (500 MHz, CDCl3) d 7.88 (bs, 1H, NH), 7.25
(d, J ¼ 8.0 Hz, 1H, H7), 7.00 (d, J ¼ 2.4 Hz, 1H, H2), 6.99 (d, J ¼ 2.5 Hz,
1H, H4), 6.87 (dd, J ¼ 8.8, 2.4 Hz, 1H, H6), 3.87 (s, 3H, CH3), 3.66 (d,
J ¼ 7.3 Hz, 2H, NCH2), 3.12 (dd, J ¼ 8.6, 6.7 Hz, 2H, Ha), 2.91 (dd,
J ¼ 8.4, 6.9 Hz, 2H, Hb), 2.68 (p, J ¼ 7.7 Hz, 1H, CH(CH2)2), 2.06e1.96
(m, 2H, CH(CH2)2), 1.93e1.83 (m, 2H, CH2(CH2)2), 1.81e1.69 (m, 2H,
CH(CH2)2). 13C NMR (126MHz, CDCl3) d 155.7 (C5’), 154.5 (C2’), 154.3
(C5), 131.5 (C7a), 127.5 (C3a), 122.5 (C2), 100.3 (C4), 56.1 (CH3), 50.6
(NCH2), 34.3 (CH(CH2)2), 27.6 (Cb), 25.7 (CH(CH2)2), 21.5 (Ca), 18.3
(CH2(CH2)2). HPLC-MS (50:95- g.t.5 min) tR 2.35 min, m/z ¼ 328.37
[MþH]þ, calcd. for [C18H21N3O3þH]þ 328.38. HRMS [ESIþ] m/
z ¼ 327.15892 [M]þ, calcd. for [C18H21N3O3]þ 327.15829.
4.3.12. 3-(Cyclopentylmethyl)-5-[2-(5-methoxy-1H-indol-3-yl)
ethyl]-1,3,4-oxadiazol-2(3H)-one (13)
Chromatography: hexane to DCM. White solid (72% yield) of mp
81e84 C. 1H NMR (500 MHz, CDCl3) d 7.88 (bs, 1H, NH), 7.25 (d,
J¼ 8.8 Hz, 1H, H7), 7.01 (d, J¼ 2.5 Hz, 1H, H2), 6.99 (d, J¼ 2.4 Hz, 1H,
H4), 6.86 (dd, J ¼ 8.8, 2.4 Hz, 1H, H6), 3.87 (s, 3H, CH3), 3.56 (d,
J ¼ 7.4 Hz, 2H, NCH2), 3.13 (t, J ¼ 7.6 Hz, 2H, Ha), 2.92 (t, J ¼ 7.6 Hz,
2H, Hb), 2.29 (p, J ¼ 7.6 Hz, 1H, CH(CH2)2), 1.70e1.59 (m, 4H,
CH(CH2)2, Hd, Hc), 1.58e1.50 (m, 2H, CH(CH2)2(CH2)2), 1.27e1.16 (m,
2H, CH(CH2)2). 13C NMR (126 MHz, CDCl3) d 155.7 (C5’), 154.5 (C2’),
154.3 (C5), 131.5 (C7a), 127.5 (C3a), 122.5 (C2), 113.7 (C3), 112.7 (C6),
112.1 (C7), 100.3 (C4), 56.1 (CH3), 50.5 (NCH2), 39.0 (CH(CH2)2), 30.1
(CH(CH2)2), 27.6 (Cb), 25.2 (CH(CH2)2(CH2)2), 21.6 (Ca). HPLC-MS
(50:95- g.t.5 min) tR 3.14 min, m/z ¼ 342.20 [MþH]þ, calcd. for




Chromatography: DCM. White solid (57% yield) of mp
118e121 C. 1H NMR (500 MHz, CDCl3) d 7.85 (s, 1H, NH), 7.38e7.33
(m, 2H, Pho), 7.32e7.30 (m, 1H, Php), 7.30e7.21 (m, 3H, Phm, H7),
6.98 (d, J ¼ 2.4 Hz, 1H, H4), 6.94 (s, 1H, H2), 6.87 (dd, J ¼ 8.7, 2.4 Hz,
1H, H6), 4.81 (s, 2H, NCH2), 3.86 (s, 3H, CH3), 3.11 (t, J ¼ 7.6 Hz, 2H,
C. Herrera-Arozamena et al. / European Journal of Medicinal Chemistry 190 (2020) 112090 15Ha), 2.90 (t, J ¼ 7.6 Hz, 2H, Hb). 13C NMR (126 MHz, CDCl3) d 156.1
(C5’), 154.3 (C5), 154.2 (C2’), 135.1 (Phi), 131.4 (C7a), 129.0 (Pho), 128.4
(Php), 128.3 (Phm), 127.4 (C3a), 122.5 (C2), 113.6 (C3), 112.7 (C6), 112.1
(C7), 100.2 (C4), 56.0 (CH3), 49.5 (NCH2), 27.6 (Cb), 21.5 (Ca). HPLC-
MS (30:95- g.t.5 min) tR 4.23 min, m/z ¼ 350.26 [MþH]þ, calcd.
for [C20H19N3O3þH]þ 350.14. HRMS [ESIþ] m/z ¼ 349.14257[M]þ,
calcd. for [C20H19N3O3]þ 349.14264.
4.3.14. 5-[2-(5-Methoxy-1H-indol-3-yl)ethyl]-3-(3-phenylpropyl)-
1,3,4-oxadiazol-2(3H)-one (15)
Chromatography: hexane to hexane:DCM 8:2. Pale yellow oil
(92% yield). 1H NMR (500 MHz, CDCl3) d 7.85 (s, 1H, NH), 7.32e7.09
(m, 6H, H7, Ph), 6.98 (bs, 2H, H2, H4), 6.85 (dd, J¼ 8.8, 2.5 Hz,1H, H6),
3.86 (s, 3H, CH3), 3.68 (t, J ¼ 7.0 Hz, 2H, NCH2), 3.12 (dd, J ¼ 8.6,
6.4 Hz, 2H, Ha), 2.91 (dd, J ¼ 8.3, 6.4 Hz, 2H, Hb), 2.58 (t, J ¼ 7.6 Hz,
2H, CH2Ph), 2.00 (p, J ¼ 7.2 Hz, 2H, NCH2CH2). 13C NMR (125 MHz,
CDCl3) d 155.9 (C5’), 154.3 (C5), 154.2 (C2’), 140.9 (Phi), 131.5 (C7a),
128.6 (Ph), 128.5 (Ph), 126.3 (Php), 122.5 (C2), 113.7 (C3), 112.7 (C6),
112.1 (C7), 100.3 (C4), 56.1 (CH3), 45.2 (NCH2), 32.7 (CH2Ph), 29.7
(NCH2CH2), 27.6 (Cb), 21.5 (Ca). HPLC-MS (50:95- g.t.5 min) tR
3.42min,m/z¼ 378.31[MþH]þ, calcd. for [C22H23N3O3þH]þ 378.44.




To a solution of 1 (150 mg, 0.58 mmol) in 5.8 mL of anhydrous
DMF, TEA (162 mL,1.16mmol), BOP (282mg, 0.64 mmol) andmethyl
amine (580 mL of a 2M solution in THF) were slowly added. The
mixture was stirred at rt overnight and the solvent was removed
under reduced pressure. The crude was extracted with EtOAc (3x10
mL) and washed with H2O (10 mL) and brine (10 mL). The organic
layer was dried over MgSO4 and the solvent was evaporated. The
residue was purified by flash chromatography (DCM to DCM:MeOH
9:1) and washed with hexane to afford derivative 16 (29 mg, 18%
yield) as a white solid of mp 145e148 C. 1H NMR (500 MHz,
DMSO‑d6) d 10.65 (bs, 1H, NHindole), 7.24 (t, J ¼ 4.9 Hz, 1H, NHCH3),
7.21 (d, J ¼ 8.9 Hz, 1H, H7), 7.08 (d, J ¼ 2.5 Hz, 1H, H2), 6.93 (d,
J ¼ 2.5 Hz, 1H, H4), 6.70 (dd, J ¼ 8.7, 2.4 Hz, 1H, H6), 3.75 (s, 3H,
OCH3), 2.99 (m, 4H, Ha, Hb), 2.75 (d, J¼ 4.9 Hz, 3H, NHCH3). 13C NMR
(126 MHz, DMSO‑d6) d 164.0 (C2’), 159.5 (C5’), 153.0 (C5), 131.3 (C7a),
127.1 (C3a), 123.2 (C2), 112.4 (C3), 112.0 (C7), 111.2 (C6), 99.8 (C4), 55.3
(OCH3), 29.0 (NHCH3), 25.8 (Cb), 22.0 (Ca). HPLC-MS (15:95-
g.t.5 min) tR 3.17 min, m/z ¼ 273.34 [MþH]þ, calcd. for




Ethyl derivative 17 was synthesized from 1 following the same
procedure as for 16, but using ethyl amine. In this case, a column
chromatography (DCM to DCM:MeOH 9:1) and a semi-preparative
HPLC separation (20:80 g t. 60 min, isocratic gradient) were
necessary to purified 17 (6 mg, 6% yield). 1H NMR (500 MHz,
DMSO‑d6) d 10.65 (bs, 1H, NHindole), 7.32 (t, J ¼ 5.6 Hz, 1H, NHCH2),
7.21 (dd, J ¼ 8.7, 0.5 Hz, 1H, H7), 7.09 (d, J ¼ 2.3 Hz, 1H, H2), 6.94 (d,
J ¼ 2.4 Hz, 1H, H4), 6.70 (dd, J ¼ 8.7, 2.4 Hz, 1H, H6), 3.75 (s, 3H,
OCH3), 3.15 (qd, J ¼ 7.2, 5.6 Hz, 2H, CH2CH3), 3.04e2.95 (m, 4H, 4H,
Ha, Hb), 1.11 (t, J ¼ 7.2 Hz, 3H, CH2CH3). 13C NMR (126 MHz,
DMSO‑d6) d 163.3 (C2’), 159.3 (C5’), 153.0 (C5), 131.3 (C7a), 127.2 (C3a),
123.2 (C2), 112.4 (C3), 112.0 (C7), 111.2 (C6), 99.8 (C4), 55.3 (OCH3),
37.3 (CH2CH3), 25.8 (Cb), 22.0 (Ca), 14.5 (CH2CH3). HPLC-MS (15:95-
g.t.5 min) tR 3.53 min, m/z ¼ 287.11 [MþH]þ, calcd. for
[C19H25N3O3þH]þ 287.34. HRMS [ESIþ] m/z ¼ 286.14359 [M]þ,
calcd. for [C15H18N4O2]þ 286.14298.4.3.17. 5-[1-(5-Methoxy-1H-indol-3-yl)propan-2-yl]-1,3,4-
oxadiazol-2(3H)-one (21)
Entitled compound was prepared in a multi-step synthesis
starting from a mixture of 5-methoxy-1H-indole-3-carbaldehyde
(18, 1.0 g, 5.7 mmol) and (carbethoxyethylidene) triphenylphos-
phorane (1.3 equiv) in DCM (50 mL) that was refluxed overnight.
Solvent was evaporated under reduced pressure to give interme-
diate 19 [68] as a white solid of mp 116e117 C (1.4 g, 95% yield)
after a column chromatography (pure hexane to hexane: EtOAc
1:1). Then, the a,b-unsaturated ester 19 (500 mg, 1.93 mmol) in
EtOH (20 mL) was treated with a catalytic amount of PdeC (5%)
under N2 atmosphere. N2 was displaced by H2 and the flask was
sealed up with a septum. A balloon with H2 was connected with a
needle to stir at rt overnight. Then, PdeC was removed by filtration
and the solvent was evaporated to dryness under reduced pressure,
obtaining 20 [69] as a white solid (500 mg, > 99% yield), which was
used without further purification. A mixture of ester 20 (360 mg,
1.38 mmol) and hydrazine hydrate in EtOH (15 mL) was heated to
150 C for 45 min under MW irradiation. After the solvent was
evaporated, DCM (10 mL) was added to the crude and the organic
layer was washed with saturated aq. solution of NaHCO3 (3x10mL),
brine (10 mL) and dried over MgSO4. Solvent was filtered and
evaporated under reduced pressure to obtain the corresponding
hydrazide, which was not isolated but identified by its HPLC-MS
data (15:95- g.t.5), tR 2.97 min, m/z ¼ 248.17 [MþH]þ, calcd. for
[C13H17N3O2þH]þ 248.30. Intermediate hydrazide was reacted with
CDI (1.2 equiv) in anhydrous DMF (10 mL/mmol) under MW-
irradiation at 120 C for 25 min. Solvent was removed and the
residue was dissolved in EtOAc, washed with H2O (3x10 mL) and
brine (10mL), dried over MgSO4, filtered and evaporated to dryness
under reduced pressure. Purification was made by column chro-
matography (hexane to hexane:EtOAc 1:1) obtaining 21 (180 mg,
48% yield) as a white solid of mp 90e93 C. 1H NMR (400 MHz,
CDCl3) d 8.40 (bs, 1H, NHCO), 7.91 (bs, 1H, NHindole), 7.25 (d,
J¼ 9.0 Hz, 1H, H7), 6.98 (d, J¼ 2.4 Hz, 1H, H2), 6.97 (d, J¼ 2.4 Hz, 1H,
H4), 6.86 (dd, J ¼ 8.8, 2.4 Hz, 1H, H6), 3.87 (s, 3H, OCH3), 3.19 (dd,
J¼ 13.7, 6.7 Hz,1H, Ha), 3.11 (h, J¼ 6.8 Hz, 1H, Hb), 2.94 (dd, J¼ 13.8,
7.0 Hz, 1H, Ha), 1.32 (d, J ¼ 6.8 Hz, 3H, CHbCH3). 13C NMR (101 MHz,
CDCl3) d 161.4 (C5’), 155.0 (C2’), 154.3 (C5), 131.4 (C7a), 127.8 (C3a),
123.4 (C2), 112.6 (C6), 112.3 (C3), 112.1 (C7), 100.4 (C4), 56.1 (OCH3),
33.7 (Cb), 29.4 (Ca), 16.9 (CHbCH3). HPLC-MS (40:95- g.t.10 min) tR
1.25 min,m/z¼ 274.22 [MþH]þ, calcd. for [C14H15N3O3þH]þ 274.29.




Derivative 23 was prepared in a multi-step synthesis as
explained below. To a solution of the commercial aldehyde 18
(500 mg, 2.8 mmol) in pyridine (20 mL), malonic acid (2 equiv) and
piperidine (13 mL/mmol) were added and themixture was stirred at
70 C overnight under N2 atmosphere. Solvent was evaporated
under reduced pressure and EtOAc was added. The organic layer
was washed with H2O (3x10 mL) and 10% citric acid solution
(10 mL), dried over MgSO4, filtered, and evaporated to dryness, to
give 22 (97% yield) as a white solid of mp 208e211 C (bibl [70].
197e200 C). Then, to a suspension of the a,b-unsaturated acid 22
(500 mg, 2.30 mmol) and activated 4 Å molecular sieves in anhy-
drous ACN (40 mL) at rt under N2 atmosphere, HOBt (1.2 equiv),
EDC$HCl (1.2 equiv) and DMAP (0.12 equiv) were orderly added.
The mixture was stirred for 3 h until the complete acid activation
and then, N2H4$H2O (excess) was added. Once finished the reac-
tion, H2O was added, extracted with DCM and washed with satu-
rated NaHCO3 (aq). The organic layer was separated and evaporated
under reduced pressure to obtain the corresponding N-
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(15:95- g.t.5), tR 1.99 min, m/z ¼ 232.39 [MþH]þ, calcd. for
[C12H13N3O2þH]þ 232.26. Intermediate hydrazide (525 mg,
2.28 mmol) was reacted with CDI (1.2 equiv) in anhydrous DMF
(20 mL) under MW-irradiation at 120 C for 25 min. Solvent was
removed and the residue was dissolved in EtOAc (10 mL), washed
with H2O (3x10 mL) and brine (10 mL), dried over MgSO4, filtered
and evaporated to dryness under reduced pressure. Purification
was made by column chromatography (hexane to hexane:EtOAc
1:1) obtaining 23 (502 mg, 1.95 mmol, 85% yield) as a white solid of
mp 206e209 C. 1H NMR (500 MHz, DMSO‑d6) d 11.53 (bs, 1H,
NHindole), 7.85 (d, J ¼ 2.8 Hz, 1H, H2), 7.49 (d, J ¼ 16.4 Hz, 1H, Ha),
7.34 (d, J ¼ 2.7 Hz, 1H, H4), 7.34 (d, J ¼ 8.5 Hz, 1H, H7), 6.82 (dd,
J¼ 8.8, 2.3 Hz,1H, H6), 6.59 (d, J¼ 16.4 Hz,1H, Hb), 3.82 (s, 3H, CH3).
13C NMR (126 MHz, DMSO‑d6) d 155.4 (C5’), 154.6 (C5), 154.4 (C2’),
132.0 (C7a), 131.1 (Ca), 129.7 (C2), 125.5 (C3a), 112.9 (C7), 112.3 (C6),
111.9 (C3), 103.9 (Cb), 101.5 (C4) 55.5 (CH3). HPLC-MS (15:95-
g.t.10 min) tR 6.04 min, m/z ¼ 258.32 [MþH]þ, calcd. for
[C13H11N3O3þH]þ 258.25. HRMS [ESIþ] m/z ¼ 257.08107 [M]þ,
calcd. for [C13H11N3O3]þ 257.08004.4.3.19. 5-[(E)-2-(5-Methoxy-1H-indol-3-yl)ethenyl]-3-(prop-2-yn-
1-yl)-1,3,4-oxadiazol-2(3H)-one (24)
Alkylation of 23 (60 mg, 0.23 mmol) with propargyl bromide
(1.2 equiv) in the presence of K2CO3 (1.2 equiv) under MW-
irradiation at 120 C for 10 min, using acetone (7 mL/mmol) as
solvent, gave 24 (12 mg, 17% yield) as a white solid of mp
201e203 C. Purification by semipreparative HPLC (gradient 35:40-
g.t.30 min). 1H NMR (400 MHz, DMSO‑d6) d 11.59 (s, 1H, NH), 7.88
(d, J¼ 2.5 Hz,1H, H2), 7.56 (d, J¼ 16.4 Hz, 1H, Ha), 7.37 (d, J¼ 2.4 Hz,
1H, H4), 7.35 (d, J ¼ 8.8 Hz, 1H, H7), 6.83 (dd, J ¼ 8.7, 2.4 Hz, 1H, H6),
6.63 (d, J¼ 16.4 Hz, 1H, Hb), 4.58 (d, J¼ 2.6 Hz, 2H, CH2), 3.83 (s, 3H,
CH3), 3.45 (t, J ¼ 2.5 Hz, 1H, ≡CH). 13C NMR (101 MHz, DMSO‑d6)
d 154.7 (C5), 154.3 (C5’), 152.1 (C2’), 132.3 (Ca), 132.1 (C7a), 130.4 (C2),
125.4 (C3a), 113.0 (C7), 112.5 (C6), 111.9 (C3), 102.9 (Cb), 101.6 (C4),
77.3 (≡C), 76.0 (≡CH), 55.5 (CH3), 35.2 (CH2). HPLC-MS (15:95-
g.t.10 min) tR 7.63 min, m/z ¼ 296.25 [MþH]þ, calcd. for
[C16H13N3O3þH]þ 296.30. HRMS [ESIþ] m/z ¼ 270.10827 [M]þ,
calcd. for [C16H13N3O3]þ 270.10044.4.3.20. (2E)-3-(5-Methoxy-1H-indol-3-yl)-N-(prop-2-yn-1-yl)
prop-2-enamide (25)
Under N2 atmosphere, to a solution of the acid 22 (100 mg,
0.46 mmol) in anhydrous ACN (15 mL/mmol) in the presence of
activated 4 Å molecular sieves, HOBt (1.2 equiv), EDC$HCl (1.2
equiv) and DMAP (0.12 equiv) were orderly added at rt. Themixture
was stirred for 3 h and then, propargylamine (1.2 equiv) was added.
Afterward, H2O was added, extracted with DCM (3x10 mL) and
washed with saturated NaHCO3 aq (10 mL). The organic layer was
separated, dried with MgSO4 and solvent evaporated under
reduced pressure. Residuewas purified by column chromatography
(hexane to hexane:EtOAc 1:1), obtaining 25 as an oil (60 mg,
0.23 mmol, 51% yield). 1H NMR (500 MHz, DMSO‑d6) d 11.44 (s, 1H,
NHindole), 8.29 (t, J¼ 5.5 Hz,1H, NHamide), 7.72 (d, J¼ 2.9 Hz,1H, H2),
7.62 (d, J ¼ 15.8 Hz, 1H, Ha), 7.34 (d, J ¼ 8.8 Hz, 1H, H7), 7.34 (d,
J ¼ 1.9 Hz, 1H, H4), 6.85 (dd, J ¼ 8.7, 2.5 Hz, 1H, H6), 6.53 (d,
J ¼ 15.8 Hz, 1H, Hb), 4.01 (dd, J ¼ 5.5, 2.5 Hz, 2H, CH2), 3.84 (s, 3H,
CH3), 3.16 (t, J ¼ 2.6 Hz, 1H, ≡CH). 13C NMR (126 MHz, DMSO‑d6)
d 166.1 (CO), 154.5 (C5), 133.9 (Ca), 132.3 (C7a), 131.0 (C2), 125.3 (C3a),
114.7 (Cb), 112.8 (C7), 111.8 (C6), 109.5 (C3), 102.5 (C4), 81.5 (≡C), 73.1
(≡CH), 55.5 (CH3), 27.8 (CH2). HPLC-MS (15:95- g.t.10 min) tR
5.80 min, m/z ¼ 255.07 [MþH]þ, calcd. for [C15H14N2O2þH]þ
255.29. HRMS [ESIþ] m/z ¼ 254.10667 [M]þ, calcd. for
[C15H14N2O2]þ 254.10553.4.3.21. (2E)-3-(5-Methoxy-1H-indol-3-yl)-N-(prop-2-en-1-yl)
prop-2-enamide (26)
Similarly, to the synthesis of 25 but using allylamine, derivative
26 was obtained (72% yield) as a pale yellow solid of mp
124e126 C. Chromatography: hexane to hexane:EtOAc 3:7. 1H
NMR (500 MHz, CDCl3) d 8.77 (s, 1H, NHindole), 7.87 (d, J ¼ 15.5 Hz,
1H, Ha), 7.40 (d, J ¼ 2.8 Hz, 1H, H2), 7.30 (d, J ¼ 2.6 Hz, 1H, H4), 7.30
(d, J ¼ 8.7 Hz, 1H, H7), 6.90 (dd, J ¼ 8.9, 2.3 Hz, 1H, H6), 6.35 (d,
J¼ 15.6 Hz,1H, Hb), 5.92 (ddt, J¼ 17.1,10.1, 5.6 Hz,1H, CH¼ ), 5.72 (t,
J ¼ 6.4 Hz, 1H, CONH), 5.25 (dd, J ¼ 17.2, 1.5 Hz, 1H, CH2trans ¼ ), 5.17
(dd, J ¼ 10.3, 1.5 Hz, 1H, CH2cis ¼ ), 4.05 (tt, J ¼ 5.8, 1.6 Hz, 2H, CH2),
3.87 (s, 3H, CH3). 13C NMR (126MHz, CDCl3) d 167.3 (CO), 155.3 (C5),
135.1 (Ca), 134.6 (CH ¼ ), 132.2 (C7a), 128.7 (C2), 126.2 (C3a), 116.6
(¼CH2), 115.2 (Cb), 113.3 (C3), 112.9 (C6), 112.6 (C7), 102.8 (C4), 56.2
(CH3), 42.3 (CH2). HPLC-MS (15:95- g.t.10 min) tR 6.12 min, m/
z ¼ 257.23 [MþH]þ, calcd. for [C15H16N2O2þH]þ 257.31. HRMS
[ESIþ] m/z ¼ 256.12237 [M]þ, calcd. for [C15H16N2O2]þ 256.12118.
4.3.22. 6-Methoxy-4-methyl-1,2-dihydronaphthalene (28)
To a solution of 7-methoxy-1-tetralone (200 mg, 1.13 mmol) in
5 mL of Et2O, CH3MgI (1.3 equiv) was added dropwise at rt. The
mixture was stirred for 3 h, washed with a saturated solution of
NH4Cl and extracted with Et2O (3x10 mL), obtaining the interme-
diate alcohol. Then, a 2 M HCl solution was added dropwise until
pH 5 and the mixture was heated at 40 C for 3 h. The layers were
separated, and the organic layer was washed with a solution of
Na2S2O3, and brine; dried over MgSO4, filtrated and the solvent was
removed under reduced pressure. The crude was purified by flash
chromatography in hexane, obtaining 28 [34] (191 mg, 1.10 mmol,
97% yield) as a colorless oil.
4.3.23. Oxidation reaction of 28 with selenium oxide
To compound 28 (238 mg, 1.37 mmol) in EtOH (5 mL), a solution
of SeO2 (5 equiv) in EtOH:H2O (15 mL, 10:1) was added dropwise
(35 min addition). The mixture was heated at reflux overnight and
then, it was extracted with EtOAc (3x10 mL) and washed with a
saturated solution of NaHCO3 (10 mL) and brine (10 mL). The
organic layer was dried over MgSO4, filtered and concentrated
under reduced pressure. The crude was purified by column chro-
matography (hexane to hexane:EtOAc 6:4) to afford 7-
methoxynaphthalene-1-carbaldehyde (30) [35] as a colorless oil
(8 mg, 20% yield) and 7-methoxy-3,4-dihydronaphthalene-1-
carbaldehyde (29) (64 mg, 25% yield) as a brown oil. 1H NMR
(400MHz, CDCl3) d 9.68 (s, 1H, COH), 7.87 (d, J¼ 2.7 Hz,1H, H8), 7.10
(d, J ¼ 8.5 Hz, 1H, H5), 7.04 (t, J ¼ 4.7 Hz, 1H, H2), 6.80 (dd, J ¼ 8.3,
2.7 Hz, 1H, H6), 3.83 (s, 3H, CH3), 2.76 (t, J ¼ 7.9 Hz, 2H, H4),
2.61e2.54 (m, 2H, H3). 13C NMR (101 MHz, CDCl3) d 192.7 (CO),
158.4 (C7), 153.7 (C2), 138.0 (C1), 130.3 (C8a), 128.4 (C5), 127.8 (C4a),
114.2 (C6), 111.4 (C8), 55.5 (CH3), 26.3 (C4), 24.8 (C3). HPLC-MS




To a solution of aldehyde 29 (280 mg, 1.49 mmol) in pyridine
(7 mL/mmol), malonic acid (2 equiv) and piperidine (13 mL/mmol)
were added and the mixture was stirred at 70 C overnight under
N2 atmosphere. Solvent was evaporated under reduced pressure
and EtOAc (10 mL) was added. The organic layer was washed with
H2O (10 mL), 10% citric acid solution (10 mL), dried over MgSO4,
filtered, and evaporated to dryness, obtaining lactone 32 as a white
solid of mp 96e98 C (23% yield). 1H NMR (500 MHz, CDCl3) d 7.10
(d, J ¼ 2.7 Hz, 1H, H10), 7.07 (d, J ¼ 8.4 Hz, 1H, H7), 6.81 (dd, J ¼ 8.4,
2.6 Hz, 1H, H8), 6.37 (dt, J ¼ 5.6, 2.7 Hz, 1H, H1), 5.15 (dtd, J ¼ 13.7,
4.4, 1.6 Hz, 1H, H4a), 3.82 (s, 3H, CH3), 3.36 (ddd, J¼ 20.6, 5.9, 1.5 Hz,
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H6), 2.42 (dq, J ¼ 12.4, 4.3 Hz, 1H, H5), 1.99 (tddd, J ¼ 12.2, 11.4, 5.0,
0.6 Hz, 1H, H5). 13C NMR (126 MHz, CDCl3) d 170.2 (C3), 158.5 (C9),
134.5 (C1b), 131.8 (C10a), 130.0 (C7), 128.7 (C6a), 114.8 (C8), 114.7 (C1),
108.0 (C10), 77.7 (C4a), 55.5 (CH3), 31.8 (C2), 29.6 (C5), 26.9 (C6).
HPLC-MS (50:95- g.t.10 min) tR 1.75 min, m/z ¼ 231.17 [MþH]þ,
calcd. for [C14H14O3þH]þ 231.26.
4.3.25. 5-[(E)-2-(7-Methoxy-3,4-dihydronaphthalen-1-yl)ethenyl]-
1,3,4-oxadiazol-2(3H)-one (33)
Lactone 32 (70 mg, 0.30 mmol) was treated with HOBt (1.2
equiv), EDC$HCl (1.2 equiv) and DMAP (0.12 equiv) in anhydrous
ACN (15 mL) in the presence of activated 4 Å molecular sieves at rt
for 3 h. Then, N2H4$H2O (excess) was added to give the corre-
sponding hydrazide, whichwas not isolated but identified byHPLC-
MS. Intermediate hydrazide was treated with CDI (1.2 equiv) in
anhydrous DMF (10mL) underMW-irradiation at 120 C for 25min.
Solvent was removed and the residue was dissolved in EtOAc,
washed with H2O and brine, dried over MgSO4, filtered and evap-
orated to dryness under reduced pressure. Purification was made
by column chromatography (hexane to hexane:EtOAc 3:7) obtain-
ing 33 (15% yield) as a white solid of mp 133e136 C. 1H NMR
(400 MHz, MeOD) d 7.11 (d, J ¼ 8.4 Hz, 1H, H5), 7.09 (dd, J ¼ 16.2,
1.2 Hz, 1H, Ha), 6.91 (d, J ¼ 2.6 Hz, 1H, H8), 6.75 (dd, J ¼ 8.2, 2.6 Hz,
1H, H6), 6.50 (d, J ¼ 16.2 Hz, 1H, Hb), 6.45 (t, J ¼ 4.8 Hz, 1H, H2), 3.78
(s, 3H, CH3), 2.66 (t, J ¼ 7.7 Hz, 2H, H4), 2.35e2.27 (m, 2H, H3). 13C
NMR (126MHz, CDCl3) d 158.5 (C7),155.6 (C5’),153.9 (C2’), 137.5 (Ca),
134.7 (C1), 133.7 (C8a), 133.1 (C2), 128.9 (C4a), 128.8 (C5), 112.4 (C6),
111.3 (Cb), 110.7 (C8), 55.6 (CH3), 27.1 (C4), 24.1 (C3). HPLC-MS
(50:95- g.t.10 min) tR 4.72 min, m/z ¼ 271.10 [MþH]þ, calcd. for
[C15H14N2O3þH]þ 271.29. HRMS [ESIþ] m/z ¼ 270.10827 [M]þ,
calcd. for [C15H14N2O3]þ 270.10044.
4.3.26. Ethyl (2E)-3-(7-Methoxy-3,4-dihydronaphthalen-1-yl)
prop-2-enoate (35)
Under inert atmosphere, Tf2O (0.6 mL, 3.31 mmol) and 2-
chloropyridine (0.3 mL, 3.31 mmol) were added to a solution of
commercial 7-methoxy-1-tetralone (507mg, 2.88 mmol) in 7mL of
dry DCM at rt. After 2 h the reaction was finished and the solvent
was evaporated to dryness. The crude was purified by flash chro-
matography on hexane, obtaining the triflate 34 [36] as colorless oil
(697 mg, 78% yield). Intermediate 34 (120 mg, 0.39 mmol) was
solved in 1 mL of anhydrous DMF under N2 atmosphere and a so-
lution of ethyl acrylate (93 mL, 0.86 mmol, 2.2 equiv), TEA (189 mL,
1.36 mmol, 3.5 equiv) and Pd(PPh3)2Cl2 (6 mg, 2.2 mol %) in 0.5 mL
of DMF was added. Reaction was heated under MW irradiation at
105 C for 15 min. DMF was evaporated to dryness and the residue
was extractedwith ether (3x10mL). Organic layer waswashedwith
H2O (3x10 mL), dried over MgSO4 and filtered. Crude was purified
by preparative TLC in hexane:EtOAc 8:2 to afford unsaturated ester
35 as a white solid of mp: 72e74 C (46 mg, 50% yield). 1H NMR
(400 MHz, MeOD) d 7.60 (d, J ¼ 16.0 Hz, 1H, Ha), 7.12 (d, J ¼ 8.3 Hz,
1H, H5), 6.87 (d, J ¼ 2.6 Hz, 1H, H8), 6.77 (dd, J ¼ 8.2, 2.7 Hz, 1H, H6),
6.56 (t, J ¼ 5.0 Hz, 1H, H2), 6.26 (d, J ¼ 15.9 Hz, 1H, Hb), 4.24 (q,
J ¼ 7.2 Hz, 2H, OCH2), 3.78 (s, 3H, OCH3), 2.66 (t, J ¼ 7.8 Hz, 2H, H4),
2.33 (td, J ¼ 7.6, 4.7 Hz, 2H, H3), 1.32 (t, J ¼ 7.1 Hz, 3H, CH2CH3). 13C
NMR (101 MHz, MeOD) d 168.8 (CO), 159.9 (C7), 144.7 (Ca), 135.7
(C1), 135.1 (C2), 134.8 (C8a), 129.9 (C4a), 129.6 (C5), 120.0 (Cb), 113.3
(C6), 111.4 (C8), 61.7 (OCH2), 55.8 (OCH3), 27.9 (C4), 25.0 (C3), 14.6
(CH2CH3). HPLC-MS (50:95- g.t.10 min) tR 5.38 min, m/z ¼ 259.11
[MþH]þ, calcd. for [C16H18O3 þH]þ 259.32.
4.3.27. 6,7-Dimethoxy-3,4-dihydronaphthalen-1-yl
trifluoromethanesulfonate (37)
Tf2O (1.1 equiv) and 2-chloropyridine (1.1 equiv) were added to asolution of commercial 6,7-dimethoxy-1-tetralone (550 mg,
2.67 mmol) in 10 mL of dry DCM at rt, under inert atmosphere.
After 2 h of reaction, the solvent was evaporated and the crude was
purified by flash chromatography (hexane to hexane:EtOAc 75:25),
obtaining 301 mg (33% yield) of 37 as a colorless oil [71].
4.3.28. 7-Methoxynaphthalen-1-yl trifluoromethanesulfonate (38)
To a solution of 34 (165 mg, 0.53 mmol) in DCM (5 mL/mmol), a
solution of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ, 1.2
equiv) in DCM (5mL/mmol) was added. Themixturewas stirred for
10 min and washed with a saturated solution of NaHCO3 (3x10 mL)
and brine (10 mL). Organic layer was dried over MgSO4, filtrated
and the solvent was removed under reduced pressure. The crude
was purified by column chromatography (hexane), giving 38 as a
colorless oil (142 mg, 88% yield) [72].
4.3.29. 6,7-Dimethoxynaphthalen-1-yl trifluoromethanesulfonate
(39)
Similarly to the synthesis of 38 but using 37 as starting material,
the 6,7-dimethoxynaphthalene derivative 39 [72] was obtained as a




To a solution of triflate 38 (220 mg, 1.70 mmol) in anhydrous
DMF (5 mL/mmol), 1,10-phenanthroline (5.5% mol), Pd(OAc)2 (5.5%
mol), TEA (1.2 equiv) and ethyl acrylate (5 equiv) were successively
added. The reaction was heated under MW irradiation at 150 C for
1 h. The solvent was evaporated and the product was purified by
column chromatography (hexane to hexane:EtOAc 95:5), giving




Similarly to the synthesis of 40, but using the triflate derivative
39 as reactant, the a,b-unsaturated ester 41 was obtained in 81%
yield as a white solid of mp 89e90 C. Chromatography: hexane to
hexane:EtOAc 85:15. 1H NMR (400 MHz, CDCl3) d 8.44 (d,
J¼ 15.7 Hz,1H, Ha), 7.74 (d, J¼ 8.1 Hz,1H, H4), 7.62 (d, J¼ 7.4 Hz,1H,
H2), 7.39 (s, 1H, H8), 7.34 (t, J ¼ 7.7 Hz, 1H, H3), 7.14 (s, 1H, H5), 6.52
(d, J ¼ 15.7 Hz, 1H, Hb), 4.32 (q, J ¼ 7.1 Hz, 2H, CH2), 4.05 (s, 3H,
CH3OC7), 4.01 (s, 3H, CH3OC6), 1.37 (t, J ¼ 7.1 Hz, 3H, CH2CH3). 13C
NMR (101MHz, CDCl3) d 167.3 (CO),150.4 (C7), 149.7 (C6), 142.1 (Ca),
130.4 (C1), 129.9 (C4a), 129.0 (C4), 127.6 (C8a), 124.1 (C3), 123.6 (C2),
120.5 (Cb), 107.1 (C5), 102.4 (C8), 60.7 (CH2), 56.2 (CH3OC7), 56.0
(CH3OC6), 14.5 (CH2CH3). HPLC-MS (50:95- g.t.10 min) tR 3.50 min,
m/z ¼ 287.27 [MþH]þ, calcd. for [C17H18O4 þH]þ 287.33.
4.3.32. (2E)-3-(7-Methoxynaphthalen-1-yl)prop-2-enoic acid (42)
LiOH (1.3 equiv) was added to a solution of 40 (100 mg,
0.39 mmol) in THF:H2O 1:1 (10 mL) and the mixture was stirred at
rt overnight. The solutionwas adjusted to pH¼ 1 by addition of 1 M
HCl. The product was precipitated, washed with H2O until neutral
pH, centrifuging to avoid losing product, and lyophilized to remove
water traces to obtain acid 42 [73] (889 mg, 0.39 mmol, >99% yield)
as a white solid of mp 212e215 C.
4.3.33. (2E)-3-(6,7-Dimethoxynaphthalen-1-yl)prop-2-enoic acid
(43)
In the same way to the synthesis of 42, from ester 41 (150 mg,
0.52 mmol) acid 43 was obtained in quantitative yield (134 mg,
0.52 mmol), as a white solid of mp 220e222 C. 1H NMR (500 MHz,
MeOD) d 8.45 (d, J¼ 15.7 Hz,1H, Ha), 7.84 (d, J¼ 8.1 Hz,1H, H4), 7.75
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(s, 1H, H5), 6.57 (d, J ¼ 15.7 Hz, 1H, Hb), 4.02 (s, 3H, CH3OC7), 3.96 (s,
3H, CH3OC6). 13C NMR (126 MHz, MeOD) d 167.8 (CO2H), 151.6 (C7),
151.0 (C6), 142.6 (Ca), 131.0 (C1), 130.9 (C4a), 129.8 (C4), 128.3 (C8a),
124.6 (C3),124.1 (C2),121.2 (Cb), 108.1 (C5),103.0 (C8), 56.0 (CH3OC7),




Acid 42 (230 mg, 1.01 mmol) was transformed into the corre-
sponding hydrazide by treatment with HOBt (1.2 equiv), EDC$HCl
(1.2 equiv) and DMAP (0.12 equiv) in anhydrous ACN (10 mL) at rt
for 3 h and then, with N2H4$H2O. The corresponding acylhydrazine
was not isolated, but identified by HPLC-MS (50:95- g.t.10 min and
2:30- g.t.10 min), m/z ¼ 243.11 [MþH]þ, calcd. for
[C14H14N2O2þH]þ 243.28. Intermediate hydrazidewas treatedwith
CDI (1.2 equiv) in anhydrous DMF (10 mL/mmol) under MW-
irradiation at 130 C for 25 min. Solvent was removed and the
residue was dissolved in EtOAc (10 mL), washed with H2O (3x10
mL) and brine (10mL), dried overMgSO4, filtered and evaporated to
dryness under reduced pressure. Purification was made by column
chromatography (hexane to hexane:EtOAc 6:4) obtaining 44
(245 mg, 91% yield) as a white solid of mp 207e208 C. 1H NMR
(500 MHz, MeOD) d 8.10 (d, J ¼ 16.1 Hz, 1H, Ha), 7.84 (d, J ¼ 8.4 Hz,
1H, H4), 7.82 (d, J ¼ 9.0 Hz, 2H, H5, H2), 7.45 (d, J ¼ 2.5 Hz, 1H, H8),
7.37 (dd, J¼ 8.0, 7.4 Hz,1H, H3), 7.20 (dd, J¼ 9.0, 2.4 Hz,1H, H6), 6.83
(d, J¼ 16.1 Hz, 1H, Hb), 3.98 (s, 3H, CH3). 13C NMR (126 MHz, MeOD)
d 160.0 (C7), 156.6 (C5’), 135.4 (Ca), 133.9 (C8a), 132.1 (C1), 131.4 (C5),
131.0 (C4), 130.8 (C4a), 126.1 (C2), 124.3 (C3), 119.9 (C6), 113.5 (Cb),
102.5 (C8), 55.9 (CH3). HPLC-MS (50:95- g.t.10 min) tR 1.83 min, m/
z ¼ 269.16 [MþH]þ, calcd. for [C15H12N2O3þH]þ 269.27. HRMS
[ESIþ] m/z ¼ 268.08547 [M]þ, calcd. for [C15H12N2O3]þ 268.08479.
4.3.35. 5-[(E)-2-(6,7-Dimethoxynaphthalen-1-yl)ethenyl]-1,3,4-
oxadiazol-2(3H)-one (45)
Similarly to the synthesis of 44, acid 43 (100 mg, 0.39 mmol)
was first transformed into the corresponding hydrazide that was
identified by HPLC-MS (2:30- g.t.10 min), m/z ¼ 273.11 [MþH]þ,
calcd. for [C15H16N2O3þH]þ 273.30. This intermediate hydrazide
was then reacted with CDI to obtain the oxadiazolone 45 (99 mg,
85% yield) as a yellow pale solid of mp 232e234 C. Chromatog-
raphy: hexane to hexane:EtOAc 6:4. 1H NMR (400 MHz, DMSO‑d6)
d 8.04 (d, J ¼ 16.1 Hz, 1H, Ha), 7.82 (d, J ¼ 8.1 Hz, 1H, H4), 7.78 (d,
J¼ 7.3 Hz,1H, H2), 7.46 (s, 1H, H8), 7.41e7.32 (m, 2H, H5, H3), 6.93 (d,
J ¼ 16.1 Hz, 1H, Hb), 3.97 (s, 3H, C7OCH3), 3.90 (s, 3H, C6OCH3). 13C
NMR (101 MHz, DMSO‑d6) d 154.4 (C5’), 154.2 (C2’), 149.9 (C7), 149.3
(C6), 133.7 (Ca), 130.1 (C1), 129.4 (C4a), 128.4 (C4), 126.6 (C8a), 123.8
(C3), 122.7 (C2), 112.6 (Cb), 107.2 (C5), 102.2 (C8), 55.6 (C7OCH3), 55.4
(C6OCH3). HPLC-MS (50:95- g.t.10 min) tR 1.22 min, m/z ¼ 299.18
[MþH]þ, calcd. for [C16H14N2O4þH]þ 299.30. HRMS [ESIþ] m/
z ¼ 298.09568 [M]þ, calcd. for [C16H14N2O4]þ 298.09536.
4.4. Pharmacology
4.4.1. Assays for human MT1R and MT2R subtypes
These experiments were performed at Eurofins-CEREP (France),
using hMT1R and hMT2R stably transfected in Chinese hamster
ovary cells (catalog refs. 1538 and 1687, respectively) [37,38]. In the
case of hMT1R cell membrane homogenates (about 80 mg protein)
are incubated for 240 min at 22 C with 0.01 nM [125I]iodomela-
tonin in the absence or presence of the test compound in a buffer
containing 50 mM Tris-HCl (pH 7.4), 5 mMMgCl2 and 0.1% BSA. For
hMT2R cell membrane homogenates (6 mg protein) are incubated
for 120 min at 37 C with 0.05 nM [125I]iodomelatonin in theabsence or presence of the test compound in a buffer containing
50 mM Tris-HCl (pH 7.4) and 5 mM MgCl2.
In both cases, nonspecific binding is determined in the presence
of 1 mM melatonin. Following incubation, the samples are filtered
rapidly under vacuum through glass fibre filters (GF/B, Packard)
presoaked with 0.3% PEI and rinsed several times with ice-cold
50 mM Tris-HCl using a 96-sample cell harvester (Unifilter, Pack-
ard). The filters are dried then counted for radioactivity in a scin-
tillation counter (Topcount, Packard) using a scintillation cocktail
(Microscint 0, Packard).
4.4.2. Binding assays in quinone reductase-2
Evaluation of the affinity of compounds for QR2 in the hamster
brain was performed by a radioligand binding assay (Eurofins-
CEREP, France, catalog ref. 0088) [39]. Membrane homogenates of
brain (750 mg protein) are incubated for 60 min at 4 C with 0.1 nM
[125I]iodomelatonin in the absence or presence of the test com-
pound in a buffer containing 50 mM Tris-HCl (pH 7.4) and 4 mM
CaCl2. Nonspecific binding is determined in the presence of 30 mM
melatonin. Following incubation, the samples are filtered rapidly
under vacuum through glass fiber filters (Filtermat B, Wallac)
presoaked with 0.5% PEI (pH 7.4) and rinsed several times with an
ice-cold buffer containing 50mM Tris-HCl and 2MNaCl using a 48-
sample cell harvester (Mach II, Tomtec). The filters are dried then
counted for radioactivity in a scintillation counter (Betaplate 1204,
Wallac) using a solid scintillator (Meltilex B/HS, Wallac).
4.4.3. Methodology and expression of the results of binding assays
in hMT1R, hMT2R and QR2
Radioligand displacements were measured at a fixed concen-
tration of compound in each receptor subtype in 3 independent
experiments. Then, compounds displaying a radioligand displace-
ment above 80% were re-evaluated using a range of 5 different
concentrations in 3 independent experiments, to determine the
binding constants (Ki). The standard reference compound was
melatonin, which was tested in each experiment at several con-
centrations to obtain a competition curve from which its IC50 was
calculated.
The IC50 values (concentration causing a half-maximal inhibi-
tion of control specific binding) and Hill coefficients (nH) were
determined by non-linear regression analysis of the competition
curves generated with mean replicate values using Hill equation
curve fitting
Y ¼ D þ [(A-D) / [1þ(C/IC50)nH]
where Y ¼ specific binding, A ¼ left asymptote of the curve,
D¼ right asymptote of the curve, C¼ compound concentration, and
nH ¼ slope factor.
The inhibition constants (Ki) were calculated using the Cheng
Prusoff equation
Ki ¼ IC50 / (1 þ L/KD)
where L ¼ concentration of radioligand in the assay, and
KD ¼ affinity of the radioligand for the receptor. A scatchart plot is
used to determine the KD. In all cases, Kis are expressed as the
mean ± SEM of three independent experiments.
4.4.4. Functional assay at human MT2R
Evaluation of the agonist activity of 44 at hMT2R expressed in
transfected CHO cells was performed by measuring its effects on
cAMP modulation using the HTRF detection method (Eurofins-
CEREP, France, catalog ref. G028-2092) [38]. The cells were sus-
pended in HBSS buffer (Invitrogen) complemented with 20 mM
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at a density of 7.103 cells/well in the presence of either of the
following: HBSS (basal control), the reference agonist at 10 nM
(stimulated control) or various concentrations (EC50 determina-
tion), or the test compound. Thereafter, the adenylyl cyclase acti-
vator NKH 477 is added at a final concentration of 5 mM. Following
10 min incubation at 37 C, the cells are lysed and the fluorescence
acceptor (D2-labelled cAMP) and fluorescence donor (anti-cAMP
antibody labelled with europium cryptate) are added. After
60 min at room temperature, the fluorescence transfer is measured
at lex ¼ 337 nm and lem ¼ 620 and 665 nm using a microplate
reader (Envison, PerkinElmer). The cAMP concentration is deter-
mined by dividing the signal measured at 665 nm by that measured
at 620 nm (ratio).
The EC50 value (concentration producing a half-maximal
response) was determined by non-linear regression analysis of
the concentration-response curves generated with mean replicate
values of three independent experiments using Hill equation curve
fitting
Y ¼ Dþ{(A-D) / [1þ(C/EC50)nH]}
where Y ¼ response, A ¼ left asymptote of the curve, D ¼ right
asymptote of the curve, C ¼ compound concentration, and
nH ¼ slope factor.
The standard reference agonist is melatonin, which was tested
in each experiment at several concentrations to generate a
concentration-response curve from which its EC50 value was
calculated.
4.4.5. Oxygen radical absorbance capacity assay (ORAC)
Antioxidant activities were measured using the ORAC method
[43], in a Polarstar Galaxy plate reader (BMG Labtechnologies
GmbH, Offenburg, Germany) with 485-P excitation and 520-P
emission filters. The equipment was controlled by the Fluorostar
Galaxy software (version 4.11-0) for fluorescence measurement.
2,20-Azobis-(amidinopropane) dihydrochloride (AAPH), (±)-6-
hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid (trolox)
and fluorescein (FL) were purchased from Sigma-Aldrich. The re-
action was carried out in 75 mM phosphate buffer (pH 7.4) and the
final reaction mixture was 200 mL. Antioxidant (20 mL) and FL
(120 mL; 70 mM, final concentration) solutions were placed in a
black 96-well microplate (96F untreat, Nunc). The mixturewas pre-
incubated for 15 min at 37 C and then, AAPH solution (60 mL,
12 mM, final concentration) was added rapidly using a multi-
channel pipette. The microplate was immediately placed in the
reader and the fluorescence recorded every minute for 80 min. The
microplate was automatically shaken prior each reading. Samples
were measured at eight different concentrations (0.1e1 mM). A
blank (FL þ AAPH in phosphate buffer) instead of the sample so-
lution and eight calibration solutions using trolox (1e8 mM) were
also carried out in each assay. All the reaction mixtures were pre-
pared in duplicate, and at least three independent assays were
performed for each sample. Raw data were exported from the
Fluostar Galaxy Software to an Excel sheet for further calculations.
Antioxidant curves (fluorescence vs. time) were first normalized to
the curve of the blank corresponding to the same assay, and the
area under the fluorescence decay curve (AUC) was calculated. The
net AUC corresponding to a sample was calculated by subtracting
the AUC corresponding to the blank. Regression equations between
net AUC and antioxidant concentration were calculated for all the
samples, measured in three independent experiments. ORAC values
were expressed as trolox equivalents by using the standard curve
calculated for each assay, where the ORAC value of trolox was taken
as 1.0.4.4.6. NRF2 induction by luciferase activity in AREc32 cells
AREc32 cells were kindly provided by Prof. Roland Wolf (Uni-
versity of Dundee, UK) [48]. AREc32 cells were cultured in DMEM
with glutamax and high glucose, supplemented with 1% penicillin-
streptomycin (10,000 units), geneticin (0.8 mg mL1) and 10% FBS,
at 37 C in a 5% CO2 air atmosphere. AREc32 cells were sub-cultured
in 96-well white plates at 2  104 cells/well density. Cells were
incubated with increasing concentrations of tested compounds in
duplicate for 24 h. Luciferase expression was assayed with the
Luciferase Assay System by luminescence in an Orion II microplate
luminometer (Berthold, Germany). Luciferase activity increase was
normalized to basal conditions considered as 1. CD (concentration
that duplicates the luciferase activity) values are expressed as the
mean ± SEM of four independent experiments in duplicate.
4.4.7. Expression of KEAP1
4.4.7.1. pET15b-6xHis-Kelch domain construction. The human Kelch
domain fragment from vector pcDNA3.1-KEAP1-HA [74] was
subcloned in pET15b-6xHIis using the following oligonucleotides
that introduce an NdeI restriction site at both ends (Forward: 50-
TCGACATATGCAGGCAGTGCCCTGCCGCCGC-30) and BamHI
(Reverse: 50-TGACGGATCCTTAGGTGACGGCCACACCCAC-30).
4.4.7.2. Expression of recombinant 6xHis-Kelch domain. The
pET15b-6xHIis-Kelch expression vector was used to express the
Kelch domain of KEAP1 as a 6xHis-fusion protein in the BL21-DE3
strain of Escherichia coli cultivated overnight at 37 C in LBmedium.
Expression was induced at an optical density A550 ¼ 0.4 by adding
isopropyl-1-thio-b-D-galactopyranoside (IPTG) to a final concen-
tration of 0.5 mM. After 3 h at 37 C temperature, cells were lysed,
and 6xHIS-fusion protein was purified using the ProBond Purifi-
cation System (Invitrogen) as described by the manufacturer.
4.4.8. Surface plasmon resonance (SPR) assays
SPR experiments were performed at 20 C with a Biacore X-100
apparatus (Biacore, GE) in PBS-T with 1 mM DTT and 2% de DMSO
(running buffer) at 25 C. The KEAP1 Kelch domain protein was
immobilized on a CM5 sensor chip (Biacore, GE) following standard
amine coupling method [75]. The carboxymethyl dextran surface of
the flow cell 2 was activated with a 7-min injection of a 1:1 ratio of
0.4 M EDC and 0.1 M NHS. The protein was coupled to the surface
with a 7-min injection at 100 mg/mL in 10 mM sodium acetate, pH
5.0. The unreacted N-hydroxysuccinimide esters were quenched by
a 7-min injection of 0.1 M ethanolamine-HCl (pH 8.0). The level of
immobilization was 7000 RUs. Flow cell 1 treated as a flow cell 2
(amine coupling procedure) without protein was used as a refer-
ence. Prior to use 10 mM stock solutions of compounds were
diluted several times until 100 mM final concentration in the
running buffer. Typically, a series of different compounds was
injected onto the sensor chip a flow rate of 45 mL/min for a period of
1 min followed by a dissociation period of 1 min. After the disso-
ciation process an extra-wash treatment was made over the flow
cells with a 50% DMSO solution. No regeneration was needed.
Sensograms data were double-referenced and solvent corrected
using the Biaevaluation X-100 software (Biacore, GE).
4.4.9. Inhibition of human monoamine oxidases (hMAO-A and
hMAO-B)
MAO inhibition measurements were evaluated following the
general procedure previously described [76]. Briefly, test drugs and
adequate amounts of recombinant hMAO-A or hMAO-B (Sigma-
Aldrich, Spain) required and adjusted to oxidize 165 pmol of p-
tyramine/min in the control group, were incubated for 15 min at
37 C in a flat-black-bottom 96-well microtest plate (BD Bio-
sciences, Franklin Lakes, NJ) placed in the dark fluorimeter
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reagent (Molecular Probes, Inc., Eugene, OR), 1 U/mL horseradish
peroxidase, and 1 mM p-tyramine. Then, the production of resor-
ufin was quantified at 37 C in a multidetection microplate fluo-
rescence reader (FLX800, Bio-Tek Instruments, Inc., Winooski, VT)
based on the fluorescence generated (excitation, 545 nm; emission,
590 nm). The specific fluorescence emission was calculated after
subtraction of the background activity, which was determined from
wells containing all components except the hMAO isoforms, which
were replaced by a sodium phosphate buffer solution. IC50 values
were the mean ± SD of three independent experiments performed
in triplicate.
4.4.10. Inhibition of human lipoxygenase-5 (hLOX-5)
The fluorescence-based enzyme method developed by Pufahl
et al. was followed [77], in 96-well microtiter plates. The assay
solution consists of Tris buffer (50 mM, pH 7.5), ethyl-
enediaminetetraacetic acid (EDTA, 2 mM), CaCl2 (2 mM), arach-
idonic acid (AA, 3 mM), ATP (10 mM), 20,70-
dichlorodihydrofluorescein diacetate (H2DCFDA, 10 mM), hLOX-5
(100 mU/well), bovine glutathione peroxidase (GPx, 25 mU/well)
and reduced glutathione (GSH, 1 mM). Compounds to be tested
were added to the test solution prior to AA and ATP, and pre-
incubated for a period of 10 min at room temperature. Then, the AA
and ATP substrates were added; the enzymatic reaction allowed to
progress for 20 min and ended by the addition of 40 mL of aceto-
nitrile. The fluorescence measurements (excitation: 485 nm;
emission: 520 nm) were performed on a FLUOstar OPTIMA (BMG
LABTECH, Offenburg, Germany). IC50 is defined as the concentration
of compound that inhibits enzymatic activity by 50% over the
control of untreated enzyme. Data were the mean ± SD of three
independent experiments performed in triplicate.
4.4.11. In vitro bloodebrain barrier permeation assay (PAMPA-BBB)
Prediction of the brain penetration was evaluated using a par-
allel artificial membrane permeation assay (PAMPA-BBB), in a
similar manner as previously described [27,29,78e80]. Pipetting
was performedwith a semi-automatic pipettor (CyBi®-SELMA) and
UV reading with a microplate spectrophotometer (Multiskan
Spectrum, Thermo Electron Co.). Commercial drugs, phosphate
buffered saline solution at pH 7.4 (PBS), and dodecane were pur-
chased from Sigma, Aldrich, Acros, and Fluka. Millex filter units
(PVDF membrane, diameter 25 mm, pore size 0.45 mm) were ac-
quired from Millipore. The porcine brain lipid (PBL) was obtained
from Avanti Polar Lipids. The donor microplate was a 96-well filter
plate (PVDF membrane, pore size 0.45 mm) and the acceptor
microplate was an indented 96-well plate, both fromMillipore. The
acceptor 96-well microplate was filled with 200 mL of PBS: ethanol
(70:30) and the filter surface of the donor microplate was
impregnated with 5 mL of porcine brain lipid (PBL) in dodecane
(20 mg mL1). Compounds were dissolved in PBS: ethanol (70:30)
at 100 mg mL1, filtered through a Millex filter, and then added to
the donor wells (200 mL). The donor filter plate was carefully put on
the acceptor plate to form a sandwich, which was left undisturbed
for 120 min at 25 C. After incubation, the donor plate is carefully
removed and the concentration of compounds in the acceptor wells
was determined by UVeVis spectroscopy. Every sample is analysed
at five wavelengths, in four wells and at least in three independent
runs, and the results are given as the mean ± standard deviation. In
each experiment, 11 quality control standards of known BBB
permeability were included to validate and normalize the analysis
set.
4.4.12. Neurogenic assays
Ten three-month-old male C57BL/6 mice were used throughoutthis study. All experimental procedures were previously approved
by the Ethics Committee for Animal Experimentation of the CSIC in
accordance with the European Communities Council, directive
2010/63/EEC and National regulations, normative 53/2013. Special
care was taken to minimize animal suffering. Neural stem cells
(NSCs) were isolated from the SGZ of the hippocampal dentate
gyrus and prepared following previously published methods
[58,81]. The isolated NSCs were seeded into 12-well dishes at a
density of ~40,000 cells per cm2 in DMEM/F12 (1:1) containing N2
medium. NSCs were grown as free-floating cells under proliferative
conditions (10 ng/mL epidermal growth factor þ 10 ng/mL fibro-
blast growth factor) allowing the formation of neural stem cells-
enriched growing spheres also called neurospheres (NS). After 7
days, with all NS having the same stage and size, cultures were
treated daily for 7 days with vehicle or 10 mM of compound 6 (10).
Now, NS were adhered onto 100 mg mL1 poly-L-lysine-coated
coverslips and treated for 3 additional days under differentiation
conditions (medium containing 1% fetal bovine serum and without
exogenous growth factors) [82]. Once neurospheres were differ-
entiated (72 h), coverslips were processed as previously described41
and used for immunofluorescence analysis. Then the expression of
neuronal markers was analysed. The following antibodies linked to
neurogenesis were used: b-III-tubulin polyclonal antibody (TuJ
clone; Abcam), a protein expressed at early stages of neurogenesis
and a monoclonal microtubule-associated protein type 2 (MAP-2)
antibody, a classical marker of late neuronal maturation. To visu-
alize primary antibodies Alexa-fluor-labelled secondary antibodies
(Molecular probes) were used. Nuclei were stained with DAPI.
Fluorescent representative images from four independent experi-
ments were acquired in a LSM710 laser scanning spectral confocal
microscope (Zeiss). Confocal microscope settings were adjusted to
produce the optimum signal to noise ratio.
4.4.13. In silico model building of ligands and proteins
The molecular graphics program PyMOL [83] was employed in
the construction of the initial molecular models, trajectory visual-
ization and 3D figure generation. Ab initio geometry optimization of
the derivatives studied was achieved using a 6-31G* basis set and
the Hartree-Fock method, as implemented in the Gaussian 09
program [84]. The SCRF ¼ (Solvent ¼ Water) option was used to
place the solute in a cavity within the solvent reaction field and
mimic hydration effects. For melatonin, 2-iodomelatonin and
resveratrol, the optimized geometries were also written in Crys-
tallographic Information File (CIF) format [85] using eLBOW [86] for
re-refinement of several human quinone reductase II (QR2) X-ray
crystal structures retrieved from the Protein Data Bank (entries
2QWX, 2QX8 [87], and 1SG0 [60]) against structure factor ampli-
tudes using Phenix [88,89] and Coot [90]. Six macrocycles were
used in each refinement round and concerted motions of atomic
groups were taken into account by means of the translation-
libration-screw (TLS) model [91]. PDB entries 6ME3 [62] and
6ME6 [63] containing the XFEL structures of chimeric MT1 and MT2
receptor constructs, respectively, in complex with 2-
phenylmelatonin were used as templates to model the complexes
of the studied compounds with the wild-type human receptors
with the aid of the Swiss-Model server [92,93]. Consequently, our
MT1 and MT2 receptor models (UniProt [94] identifiers P48039 and
P49286, respectively) contained the original truncations at both
termini but had all the introduced point mutations replaced by the
natural amino acids and a short added sequence bridging the ICL3
gap (residues 219e227 and 232e240 in MT1 and MT2 receptors,
respectively). The conserved disulfide bridge between C1003.25 and
C177ECL2 in MT1 and between C1133.25 and C190ECL2 in MT2 were
explicitly defined.
Atom-centered charges for all ligands were calculated on the 6-
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Tools17 and the default AM1-BCC option [96], so as to reproduce
the molecular electrostatic potential in a way consistent with the
ff14SB force field parameter set [97] in AMBER 16 (http://ambermd.
org).4.4.14. Molecular docking
The protein in the X-ray crystal structure of KEAP1 Kelch
Domain was prepared with the Protein Preparation procedure as
implemented in Maestro. All hydrogens were added and the charge
states of titratable amino acids were defined using the PROTKA
procedure, followed by H-bond optimization and constrained
relaxation to 0.2 rmsd tolerance. The resulting structures were used
to generate docking grids and perform docking studies with com-
pounds 23 and 24 using GLIDE [98]. The ligands were prepared
with the LigPrepmodule using the parameters of OPLS3 Force Field.
Generation of possible tautomers was done with Epik routine in
Maestro at pH range of 7 ± 2. All the modelling was done with
Maestro 11.5 Release 2018-1 (Schrodinger LLC).4.4.15. Molecular dynamics simulations
The complexes of 44 with MT1R and MT2R were embedded in a
lipid bilayer made up of 240 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC) and 21 cholesterol molecules with the
aid of the web-based CHARMM-GUI Membrane Builder graphical
user interface [99]. The system size along the Z axis was determined
by specifying a 10 Å thickness of 150 mM NaCl aqueous solution on
each side of the membrane. The AMBER ff14SB [97] and lipid14
[100] force fields were used for protein and lipids, respectively.
For each complex studied, all hydrogens and water molecules
were first reoriented in the electric field of the solute and then all
protein residues, ligands and waters were relaxed by performing 25
000 steps of steepest descent followed by 25 000 steps of conjugate
gradient energy minimization. The resulting geometry-optimized
coordinate sets were then heated up to 300 K using the Langevin
thermostat; thereafter the temperature was maintained at 300 K
whereas the system’s dimensions and density were equilibrated at
a constant pressure of 1 atm by means of an anisotropic Berendsen
weak-coupling barostat, essentially as described [100]. The uMD
simulations were run for 200 ns using the pmemd.cuda code [101],
as implemented in AMBER16, running on single Nvidia® GPUs. The
coupling constants for the temperature and pressure baths were 1.0
and 0.2 ps, respectively. The application of SHAKE to all bonds
allowed an integration time step of 2 fs to be used. A cutoff distance
of 9 Å was selected for the nonbonded interactions and the list of
nonbonded pairs was updated every 25 steps. Periodic boundary
conditions were applied and electrostatic interactions were rep-
resented using the smooth particle-mesh Ewald method [102] with
a grid spacing of 1 Å. Trajectory snapshots were saved every 0.1 ns
for further analysis. Besides, a simulated annealing procedure [103]
was followed every 5 ns to cool the system down from 300 to 273 K
over a 1-ns period. Thereafter the geometries of these “frozen”
complexes were optimized by carrying out an energy minimization
until the root-mean-square of the Cartesian elements of the
gradient was less than 0.01 kcal mol1 Å1. A similar procedurewas
used to simulate the fully solvated complexes of human QR2 with
compounds using our refined structure from PDB entry 1SG0; in
these cases, however, we found it necessary to add distance re-
straints (100 kcal mol1 Å2) to the Zn2þ coordination sphere and
weak positional restraints (1 kcal mol1 Å2) to the Ca trace of the
protein. The highly converged ensemble of 40 low-energy config-
urations thus obtained for each complex is expected to represent
more accurately the global energy minimum than isolated trajec-
tory frames [104,105].4.4.16. Potentiometric pKa determination
Titrations were carried out at 25 C in 0.15 M KCl solution (aq) in
a SiriusT3 equipment (Sirius Analytical Instruments Ltd, East Sus-
sex, Britain) equipped with an Ag/AgCl double junction reference
pH electrode, a Peltier temperature system and a turbidity sensor.
Standardized 0.5 M KOH and 0.5 M HCl were used as titration re-
agents. KOH solutionwas standardized by potassium phthalate. The
pKa value is the mean of 3 titrations ± SD [106].
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